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Abstract 
 
 
This thesis summarizes the work I have done during my PhD training, focused on the 
immune microenvironment of pancreatic adenocarcinoma (PDAC). The aim was to 
delineate key features of immunologic and tumour components shaping the biology of 
pancreatic cancer. Immunotherapy has been largely explored as a promising anticancer 
approach but not convincingly introduced yet for this tumour type. The results here 
summarized could contribute to a better understanding of the microenvironment of human 
PDAC and foster the introduction of immunotherapeutic strategies into the clinical practice. 
The first section of the thesis summarizes the work done to investigate the occurrence of 
tertiary lymphoid tissue (TLT) in PDAC. TLT has been demonstrated to coordinate the 
recruitment and activation of adaptive immune cells in several tumour settings. This work 
documents the occurrence of TLT in pancreatic cancer, addresses the prognostic role of B 
cells according to their spatial distribution within TLT and tests the hypothesis that TLT can 
serve as immunological sites that contribute to efficacy of immunotherapeutic vaccination. 
The second section is focused on the intersection between cancer metabolism and immune 
function in PDAC. In order to unearth early metabolic alterations in PDAC, we have analyzed 
the pancreatic juice, a relatively unexplored liquid biopsy potentially enriched with tumor-
derived metabolites. Our results indicate a specific metabolic signature that allows to single 
out PDAC from other pancreatic pathologies and reveal an important link between glucose 
metabolism and accumulation of PD-1+ cells in PDAC tumors. 
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1. Immune infiltrate of 
solid tumours 
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1.1 Introduction 
 
The tumour microenvironment refers to the site wherein tumour cells interact with 
surrounding or recruited host cells. It is established in literature that these interactions are 
strongly related to an inflammatory condition, given by the intrinsic ability of the tumour mass 
to recruit immune and inflammatory cells [1].  
The role of the tumour microenvironment has been closely investigated in the last decades, 
and so far it has been considered of primary importance for the evolution of the disease. In 
light of recent knowledge, tumour-infiltrating leukocytes are potentially able to exert both 
pro- and anti-tumour functions. Generally, the tumour microenvironment is largely infiltrated 
by adaptive and innate immune cells, and it has been demonstrated that both compartments 
can either sustain tumour development or mediate its rejection, depending on their 
phenotype [2-5].  
In this first part of the introduction, I will give an overview of the variety of immune cells that 
populate the tumour microenvironment.  
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1.2 Innate immune cells and cancer-related inflammation 
 
The paradoxical pro-tumour behaviour of innate immune cells can be ascribed to the 
opposite actions that these cells have to fulfil during the inflammatory response. During 
inflammation, innate immune cells have to support the adaptive immune system to 
specifically target infectious agents, and on the other side, the same cells are also involved 
in the wound-healing process required for the recovery from the damage induced by 
inflammation, supporting thus angiogenesis, tissue remodelling, and secretion of epithelial 
or stromal growth factors [2-4, 6, 7]. Neoplastic cells can subvert the intrinsic plasticity of 
innate immune cells in a double-edged sword manner, exploiting such wound-healing 
functions to sustain cancer neo-genesis and progression.  
Inflammation is an immune-mediated response that spontaneously occurs during cancer 
development. Cancer-related inflammation, mainly promoted by the innate immune system, 
affects the tumorigenic process modulating cellular proliferation, rate of mutagenesis, and 
angiogenesis [2-4]. Accordingly, it has been reported that 15-20% of human cancers are 
associated to a chronic inflammatory condition. Helicobacter Pylori, Papilloma virus, and 
Hepatitis B or C virus infections are considered risk factors for gastric cancer, cervical cancer 
and hepatocellular carcinoma respectively [2-4].  
Inflammation has been recognized as an important factor in enhancing cancer occurrence, 
and it has been recently integrated as a new ‘hallmark of cancer’ [1]. Essentially, 
inflammatory cells sustain incipient neoplasia in the acquirement of hallmark capabilities by 
limiting cell death, through secretion of growth and survival factors, by affecting 
neovascularization processes, and by sustaining metastatic progression, with the activation 
of EMT programs and secreting extracellular matrix-modifying enzymes. 
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1.3 Adaptive immune cells 
 
Seminal studies have been conducted elucidating the role of adaptive immune cells in the 
anti-tumour response, focusing almost exclusively on T lymphocytes [4, 8]. Wide 
international efforts have shown a clear association between the density of tumour infiltrating 
lymphocytes (TILs) and patient prognosis in different types of tumours [9]. It is indeed well 
accepted that tumour infiltrating T cells, namely CD4 or CD8 expressing cells, are major 
players in immune mediated anti-tumour response. Both of them have essential roles in 
limiting tumour incidence and controlling the growth of already established tumours, through 
either cytokine secretion (CD4 or helper T cells), or mediating direct tumour cell killing (CD8 
or cytotoxic T cells) [10]. Evidence has been produced demonstrating an increased 
incidence of neoplastic diseases in immunocompromised conditions, such as in Rag2-/- mice 
(i.e. mice lacking adaptive immune cells) [8] or, more specifically, in mice with impaired T 
and NK cell functions [11-13]. These works underline the fundamental role of adaptive 
immune cells in controlling tumour incidence and progression, with particular attention to 
major pathways involved, such as the production of cytotoxic molecules (Perforin), 
inflammatory cytokines (IFN-g), and the interaction of immunoregulatory receptors/ligands 
(Fas/Fas-L). Similar evidence, of increased cancer incidence in immunocompromised 
individuals, has been reported also in patients affected by acquired immunodeficiencies 
primarily involving the adaptive branch of the immune system [14-16]. This data confirms a 
major role for adaptive immune cells, and particularly T cells, in the tumour context. The 
antigen-specific antitumor function of CD8 and CD4 T cells has been exploited in conceiving 
novel antitumor therapies, namely immunotherapies, that produce antitumor effects by 
stimulating immune cells. Within immunotherapies, most promising are those that exploit T 
cell-mediated tumour control. I will discuss such approaches in paragraph 1.5 of this section.  
The other major component of tumour infiltrating adaptive immune cells is represented by B 
cells. Despite their biological relevance and high frequency in the tumour microenvironment, 
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B cells have been far less studied in cancer setting. Currently, in other pathological 
conditions such as in preclinical models of autoimmunity and transplantation, evidence has 
been produced pointing to the central role of B cells in coordinating T cell responses [17-
19]. B lymphocytes can sustain the immune response producing cytokines/chemokines, 
such as IFN-γ, IL-12 and TNF-α [20] or by activation of T cells acting as professional antigen 
presenting cells (APC) [21]. On this last point, it has been demonstrated that B cells are fully 
equipped to activate CD4 T cells by expression of various co-stimulatory proteins (CD80, 
CD86, and CD40) and MHC-II (major histocompatibility complex-class II) molecules, but 
also CD8 T cells, through a mechanism known as cross-presentation of extracellular 
antigens on MHC-I [22-24]. It has been also hypothesized that in the tumour 
microenvironment, B cells could be even superior as APC than dendritic cells (generally 
considered the most efficient APC) [25, 26]. In fact, within the tumour tissue, B cells are the 
most frequent cell type able to perform cross-presentation of antigens [25, 26] and more 
importantly, they can accumulate rare antigens by high-affinity membrane bound 
immunoglobulins [27]. Finally, B cells are suited to act directly within tissues, by activating 
cytotoxic pathways, or by production of antibodies [28]. Although B cells are biologically able 
to initiate and mediate an effective antitumor immune response, their role in human solid 
tumours is still debated. In ovarian cancer, non-small cell lung carcinoma and cervical 
cancer, B cell infiltration was associated with improved survival and lower metastasis 
incidence [23, 29, 30]. However, other studies report that antibody secreting CD138+ B cells 
are associated to poor prognosis in epithelial ovarian cancer [31]. In the same study the 
production of tumour-specific antibodies was associated to late stage disease in 50% of 
patients [31]. 
Data regarding the dichotomy of B cell role in human cancer are scant and controversial, 
nonetheless it could open the way to the reappraisal of B cell function in tumours and foster 
efforts towards novel therapeutic interventions [32]. Beside a detailed characterization of B 
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cell phenotype and a deeper knowledge of the immune pathways that B lymphocytes can 
activate in the anticancer response, their localization in the tumour microenvironment is 
equally gaining a lot of importance. In fact, as illustrated in the next paragraph and in the 
first part of this thesis, B cells display distinct patterns of distribution in the tumour 
microenvironment, and their role in those topological localization is likely to be functionally 
different [33]. 
  
1.4 Tertiary Lymphoid Tissue 
 
Effective anti-tumour immune responses are generated by cellular interactions occurring in 
the context of lymphoid organs. Recently, experimental and clinical studies have suggested 
that this oversimplified model could not be exclusive. Robust evidence indicates that during 
the course of chronic inflammatory or infectious reactions, initiation of adaptive immune 
responses and priming of naïve T cells can occasionally occur extra-nodally, in peripheral 
tissues, within structures defined as tertiary lymphoid tissue or structures (TLT, or TLS) [34-
39]. Tertiary lymphoid tissue is a well-defined topological and immunological compartment, 
capable of sustaining the recruitment of lymphocytes from the blood [40-42] and potentially 
behaving as a functional immune site involved in the generation of adaptive immune 
responses. The occurrence of TLT in tumour tissues has recently begun to be documented, 
providing evidence of an important role of TLT in the organization of immune response in 
cancer.  
The specialized microarchitecture of TLT suggests that it could serve important immune 
functions, including the organization of B cell and T cell responses, clonal expansion, 
antibody generation, and immunoglobulin class switching. For these reasons, TLT 
occurrence and function in pathological conditions are now being deeply investigated. The 
general consensus is that in certain pathological conditions, such as autoimmune diseases 
and chronic infections, the presence of a lymphoid site could support disease progression, 
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acting as an alternative site for (self-)reactive lymphocyte recruitment and activation [38, 43-
45]. Given its role in initiating and sustaining an antigen specific immune response, TLT 
could “protect” the organism by restraining pathological insults, as in the case of infectious 
diseases. In particular, over the last years, the possibility that functional ectopic lymphoid 
tissue generates an efficient immune response in tumours has propelled research towards 
the definition of its occurrence in the tumour microenvironment, with the attractive 
perspective of identifying novel targets for immunotherapeutic approaches.  
The literature available on the occurrence of TLT in the tumour microenvironment has grown 
in the last years and evidence has been provided that the aggregation of lymphocytes into 
architecturally organized structures is an important immune feature that should not be 
ignored. The presence of TLT has been documented in many tumours	[37, 46], including 
lung [47], melanoma [48], colon [41, 49, 50], breast [51]. However, not every patient with a 
specific type of cancer develops TLT and, when it is present, its density, level of organization 
and contribution to disease varies considerably. TLT develops more frequently in some 
tumour types than in others, suggesting that certain tumours provide a microenvironment 
that appears as a permissive milieu for lymphoid neo-genesis [52].  
The emerging evidence that adaptive immune responses can be triggered independently of 
secondary lymphoid organs is encouraging to deepen the general knowledge of TLT. The 
presence of TLT in tumours could represent an ectopic immune site for tumour antigen 
presentation and lymphocyte activation to take place. On the other hand, the pro-tumour 
role of chronic inflammation suggests that TLT may also represent a source of growth factors 
and pro-angiogenetic factors that sustains tumour progression [53]. Moreover, lymphatic 
vessels associated to TLT may provide an additional way for cancer cells to metastasize.  
Due to the inability of cancer preclinical models to recapitulate the chronic inflammatory 
microenvironment of human cancer, murine models of TLT neo-genesis in cancer settings 
have not been generated so far. Therefore, the most suitable approach so far to study the 
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role of TLT in cancer has been to investigate its occurrence in large cohorts of patients and 
analyse its prognostic value as reported by M. C. Dieu-Nosjean et al. [37] (Table 1 adapted 
from [37]). 
The evaluation of TLT in the tumour microenvironment as a novel biomarker of antitumor 
response has been an important objective of my project. 
 
Table 1. Evaluation of TLT clinical relevance in solid tumours. 
 
  
Primary or 
metastasic tumors Cancer types
Markers quantified 
within lymphoid 
aggregates by 
immunochemistry
Gene signature 
associated with 
TLS presence
Studied cases Stages of the disease Prognostic value
FoxP3+ cells ND 191 patients Stage II to III Negative
PNAd+ HEV ND 146 patients Stage I to III Positive
ND
Tfh, Th1, and 
CXCL13 gene 
expression
70 patients Stage I to III Positive
DC-Lamp+ mature 
DC
ND 146 patients Stage I to III Positive
CD3+ T cells and 
CD83+ mature DC
ND 40 patients Stage I to IV Positive
ND 12-Chemokine gene 
signature
21 patients Stage 0 to IVA Positive
DC-Lamp+ mature 
DC
ND 25 patients ND Positive
ND CXCL13 and CD20 
gene expression
125 patients Stage I to IV Positive
CD3+ T cells ND 351 patients Stage II to III Positive
Lymphoid follicles ND 350 patients Stage I to IV Positive
DC-Lamp+ mature 
DC
ND 74 patients Stage I to II Positive
DC-Lamp+ mature 
DC
ND 362 patients Stage I to IV Positive
DC-Lamp+ mature 
DC and 
CD20+follicular B 
cells
ND 74 patients and 122 
patients
Stage I to II and 
Stage III
Positive
DC-Lamp+ mature 
DC
ND 82 patients Stage IA to IIIA Positive
ND 12-Chemokine gene 
signature
21 patients Stage IV Positive
Renal cell carcinoma DC-Lamp
+ mature 
DC
ND 52 patients ND Negative
DC-Lamp+ mature 
DC
ND 70 patients ND Positive
DC-Lamp+ mature 
DC
ND 140 patients ND Positive
Primary tumors
Breast carcinoma
Colorectal carcinoma
Lung carcinoma
Melanoma
Metastatic tumors
Colorectal carcinoma
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1.5 Immunotherapy in solid tumours 
 
Research on cancer immunology is moving from the mechanistic comprehension of immune 
cell behaviour in the tumour microenvironment, to the translation of such knowledge to the 
clinical practice. Novel immunotherapeutic strategies have the aim to commit the immune 
system to exert its fight against cancer, by directly boosting the immune response or by 
reverting the immunosuppressive microenvironment [54]. The ability of the immune system 
to control tumour growth has been the subject of intense debate in the last century [55]. 
Here I will provide an overview of the approaches used so far to develop effective 
immunotherapeutic agents. Immunostimulating cytokines, such as GM-CSF, IL-2 and IFNa 
have been widely tested in different clinical trials, in order to boost immune cells recruitment 
to the tumour site, and sustain their effector functions [55-57]. Such immunotherapies have 
been successfully applied in clinical practice, but their therapeutic effect is limited in duration 
and restricted to few tumour conditions. Moreover, this strategy relies on the recruitment 
and stimulation of a wide range of immune cells subtypes, leading to important side effects 
that curbed the use of such immunostimulatory agents in clinical practice [58-60]. Beside 
the non-specific immune cell recruitment mediated by systemic administration of 
immunostimulatory cytokines, other strategies act by boosting antigen-specific immune 
responses. From this perspective, tumour vaccines are treatments that stimulate adaptive 
immune cells against known tumour antigens, by the direct administration of tumour 
peptides (peptide-based vaccines) [61], by the infusion of APC previously exposed to 
tumour antigens (mainly dendritic cell-based vaccines) [62], or by administration of 
autologous tumor-specific effector cells (adoptive cell transfer, ACT) [63]. More recently, the 
attention in the onco-immunology field has been catalysed by the encouraging results 
obtained with the FDA-approved checkpoint inhibitor therapies. Immunotherapeutic 
approaches with checkpoint inhibitors are based on antagonistic antibodies directed against 
immunosuppressive receptors (immune checkpoint) expressed on tumour infiltrating 
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leukocytes. Such treatments prevent immune cells in the tumour microenvironment from the 
otherwise frequent activation of inhibitory checkpoints. The PD1 receptor, expressed by T 
cells, and its ligands PD-L1/L2, expressed by tumour as well as other cells, constitute a 
predominant immune checkpoint axis operating in the tumour context. In the last few years, 
antibodies inhibiting the PD1 receptor or its ligands have been the most attractive 
immunotherapeutic strategy among checkpoint inhibitors [64]. In light of striking results in 
terms of disease remission in the clinical setting, the FDA has approved therapies based on 
antibodies targeting the PD1-PDL1 axis for the treatment of melanoma, lung cancer, and 
renal cell carcinoma [65-67].  
Despite invaluable outcomes reached by checkpoint inhibitor treatments, a considerable 
proportion of not-responding patients is still documented in most clinical trials. The ever-
growing knowledge of immune checkpoint pathways will provide further biomarkers for pre-
treatment prediction and on-treatment evaluation of patients’ response.  
 
1.6 Immune biomarkers 
The dynamic equilibrium of pro- and anti-tumour immune networks differs along stages and 
types of tumour disease, and increasing literature points to the immune infiltrate as a novel 
and appealing parameter for tumour staging and classification [68, 69]. However, the 
identification of tumour-specific immune profiles as well as the design of effective 
immunotherapeutic settings are challenged by the intrinsic heterogeneity of solid tumours. 
The function and prognostic relevance of tumour-infiltrating immune cells can vary according 
to the organ of origin and/or the stage of disease, and critically contributes to the complexity 
of the cancer microenvironment [70-72]. 
The current TNM staging system focuses primarily on tumour cells and views tumour 
progression as a cell-autonomous process without considering the host immune response 
[68-70]. It is based only on tumour invasion parameters, provides limited prognostic 
	 16	
information and does not predict response to therapy. In some patients, advanced-stage 
cancer can be stable for years, and, although rare, partial or full regression of metastatic 
tumours can occur spontaneously [9].  
Given the limitations of the TNM system and the important value of immune cells, new 
systemic and local immunological biomarkers can represent a significant innovative strategy 
in the prediction of outcome and response to therapy. Evidence demonstrating the impact 
of immune-classification in several human cancers is always growing. Immune classification 
has a prognostic value that may strengthen the value of the TNM classification, providing 
more information and facilitating clinical decision. As mentioned already, immune infiltrate 
is heterogeneous among tumour types, and is different from patient to patient. Compared to 
earlier studies assessing the relevance of tumour-infiltrating lymphocytes (TILs) in human 
cancer, current approaches have been ameliorated by integrating the analysis of adaptive 
cells with the definition of specific subsets and their quantitative distribution in the tumour 
microenvironment. The analysis of location, density and functional orientation of different 
immune cell populations is named “immune contexture” [69]. The clinical translation of the 
studies demonstrating the prognostic value of the immune contexture in primary tumours 
has led to the definition of an Immunoscore, a grading of tumours based on immune-
histological features	[70].  
Histo-pathological analyses of tumours have shown that the immune infiltrate is not 
randomly distributed: TILs are found within dense infiltrates in the centre of the tumour (CT), 
at the invasive margin (IM) of tumour nests and in stromal tertiary lymphoid tissue (TLT) 
[73]. In particular, the spatial aggregation of immune cells occupies a critical position in 
dictating patient outcome, as I will show in the first part of my thesis. 
In summary, evaluation of the histo-pathological immune reaction occurring in cancer may 
provide novel information on prognosis and might contribute to identify patient subgroups 
more likely to benefit from immunotherapy. 
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1.7 Immune infiltrate of pancreatic cancer 
My PhD project has been focused on pancreatic cancer. In order to contextualize the role 
of tumour infiltrating immune cells and how they might contribute in improving both disease 
diagnosis and treatment, in this paragraph I will introduce pancreatic cancer and provide an 
overview of available literature regarding the immune infiltrate characterizing this pathology.  
Pancreatic cancer can be classified according to the histological features of tumour cells, 
allowing identification of several tumour types, each showing distinct clinical behaviour and 
genetic profile. Within pancreatic cancers, the most common histo-type is represented by 
pancreatic ductal adenocarcinoma (PDAC), accounting for greater than 85% of pancreatic 
neoplasms [74]. PDAC is the fourth leading cause of death, with a five-year survival rate of 
less than 8% and is only modestly responsive to anticancer therapies [75]. PDAC genetic 
models showed that the immune infiltrate is mainly composed of immunosuppressive cells 
since the very early phases of the disease	[76]. This evidence has been confirmed in human 
studies, showing that alternatively activated macrophages [77]	 [78], myeloid derived 
suppressor cells	[79]	[80], and Treg cells [81] are dominant within PDAC microenvironment, 
while immune effector cells are present in low numbers or are poorly cytotoxic [82]. These 
observations supported clinical efforts aimed to target immune effector cell populations 
using immune-checkpoint blockade therapies [83]	[84]. The presence of endogenous anti-
tumour T cells strongly improved the efficacy of anti-tumour checkpoint immunotherapies, 
suggesting that modulation of the immune composition in PDAC, in particular T cells, may 
offer clinical benefit in controlling PDAC progression [85]. Moreover, PDAC is characterized 
by the formation of a dense fibrotic desmoplastic reaction, that has been reported to 
represent a barrier limiting the delivery of chemotherapy [86]	[87] and possibly the access 
of immune cells [88]. The clinical relevance of the microenvironment regarding tumour 
progression and determining disease recurrence is supported by preliminary data 
	 18	
suggesting a correlation between poorer outcome and the presence of desmoplastic 
reaction as well as the composition/quantity of tumour infiltrating immune cells resulting in a 
weaker adaptive immune response in PDAC [89]	 [90]. Not surprisingly several attempts 
have been made to evaluate the prognostic significance of tumour-infiltrating leukocytes in 
a variety of human non-PDAC cancers at the level of genomics, transcriptomics and 
histology [5]. Prognostic significance of pronounced leukocyte infiltration has been shown to 
be of associated with increased survival [5].  
It is generally accepted that PDAC microenvironment is immunosuppressive and thus 
effective antitumor immune response is dampened. In this scenario, immunotherapeutic 
approaches should be prompted at reverting the immunosuppressive mechanisms that 
dominate PDAC contexture, in order to redirect the dysfunctional immune microenvironment 
in an effective antitumor immune response. 
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2. Tumour Metabolism 
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2.1 Introduction 
Recently, many efforts have been made on shedding light on the complex interconnection 
between cancer, immune cells and metabolism. Overall, metabolic reprogramming is a well-
described event, and, in the tumour setting, it has been frequently documented as a feature 
of both cancer and infiltrating immune cells [1, 91]. The metabolic reprogramming occurring 
in cancer cells is currently investigated as a source of promising targets for novel therapeutic 
strategies. Moreover, a careful evaluation of the metabolic profile of cancer cells might pave 
the way to the discovery of biomarkers able to predict patients’ prognosis and treatment 
responsiveness [92, 93]. On the immune side, the limited nutrient availability imposed by 
tumour cells determines a cascade of metabolic adaptations in tumour-infiltrating immune 
cells. In the last decades, metabolism has emerged as a key feature in implementing our 
knowledge on immune cell biology [94] and might constitute a promising source to 
ameliorate anticancer immunotherapies. 
In this second part of the introduction, I will describe the main features of tumour metabolism, 
focusing on the possible implications for cancer immunotherapy. The effect of metabolic 
cues on immune cells infiltrating pancreatic cancer has been object of my studies and 
summarized in the second part of this thesis. 
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2.2 The Warburg Effect  
 
Non-proliferating cells in normal tissues preferentially metabolize glucose to pyruvate and 
then, in order to maximize the production of ATP, they completely oxidize pyruvate into CO2, 
in a process called oxidative phosphorylation (OXPHOS) [95]. OXPHOS requires oxygen to 
be engaged, and in conditions of normal availability of oxygen it is the principal pathway 
used by non-proliferating normal cells. However, in hypoxic conditions, OXPHOS is inhibited 
and ATP production is sustained by anaerobic glycolysis, a pathway that completely oxidizes 
pyruvate into lactate, producing far less ATP compared to OXPHOS. In contrast to what 
documented in normal non-proliferating cells, the physicist O. Warburg demonstrated that 
cancer cell metabolism relies primarily on glycolysis, even in normoxic conditions [96]. Since 
glycolysis is a pathway usually associated to hypoxia, its occurrence under normoxic 
conditions has been called aerobic glycolysis or Warburg effect. 
As mentioned above, OXPHOS is more efficient than glycolysis in producing ATP, thus it is 
reasonable to suppose that ATP production is not the main purpose of glucose metabolism 
in cancer cells. It has been demonstrated that glycolysis is 100 times faster than OXPHOS 
[97], and this could result in a rapid modulation of energy production. Moreover, several 
intermediates of the glycolytic pathway are required for the biosynthesis of important 
constituents of cell organelles, such as lipids, nucleotides and amino acids. Given its role in 
both ATP production and biomass synthesis, glycolysis is preferred over OXPHOS by 
cancer cells [98]. In addition to highly proliferating neoplastic cells, activation of aerobic 
glycolysis characterizes almost all dividing cells, in order to meet their energetic and 
biosynthetic demands [99-101]. This includes embryonic progenitor cells, adult stem cells 
and activated immune cells.  
Focusing on immune cells, the term immunometabolism refers to metabolic changes 
occurring in leukocytes during the effector phase of the immune response. In the last 
decades, much attention has been given to this peculiar feature of anti-tumour immune 
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responses, i.e. the key molecules and mechanisms driving the metabolic adaptation of 
immune cells occurring in this context [94, 102]. The metabolic reprogramming which 
characterizes the immune response to tumours is discussed below. 
 
2.3 Metabolic reprogramming of immune cells in cancer 
 
Upon activation, immune cells are metabolically reprogrammed to sustain massive 
proliferation and to mediate effector functions. Activated immune cells can adapt their 
metabolic requirements resembling characteristics of cancer cells, in order to fulfil their 
energetic demand, and to increase both biomass and effector molecule production [98]. 
Such modulation affects many of the known pathways involved in cell homeostasis, namely 
glycolysis, OXPHOS and fatty acid oxidation (FAO), depending on the cell type involved and 
on the context in which immune cell activation occurs. The dissection of the metabolic 
reprogramming that takes place in immune cells has been finely reviewed [94]. Here I will 
focus on effector T cells, which have been extensively characterized in several tumour 
settings, and display a clear role in mediating the anti-tumour immune response. 
T cells undergo metabolic adaptation when raised against their cognate antigen. Since 
activated T cells share almost the same metabolic requirements with cancer cells, it has 
been postulated that a metabolic competition for nutrients might exist in the tumour 
microenvironment. One of the most elegant descriptions of such interplay has been recently 
addressed in a paper from Dr. Pearce’s group, in which the authors demonstrated that not 
only the glucose metabolism of cancer cells profoundly impacts on tumour growth [103], but 
also that the enhanced glucose consumption of cancer cells restricts tumour infiltrating T 
cells, by inhibiting mTOR and glycolytic pathways and suppressing IFN-γ production. This 
suggests that tumour metabolism can promote cancer development by modulating antigen-
specific immune response. 
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Another interesting aspect of the interplay between immune cells and tumour metabolism is 
represented by the immunomodulating role exerted by metabolites generated through the 
aberrant tumour metabolism, also referred to as oncometabolites [104-107]. Generally, 
soluble factors released by tumour cells have been reported to mediate 
immunosuppression, thus favouring the immunological escape frequently observed during 
cancer progression. An example of the immunomodulation mediated by oncometabolites is 
represented by the lactate released by cancer cells activating the Warburg effect. Lactate 
has been shown to critically affect activation and differentiation of myeloid cells, through 
induction of hypoxia-inducible factor 1 (HIF-1) signaling. Moreover, tumour-derived lactate 
blocks the activation of T cells, inhibiting the downstream activation of key transcription 
factors, hence impairing their effector functions [107], and contributes to extracellular pH 
lowering, affecting T cell survival signals [108]. 
Tumour metabolism is emerging as a critical regulator of the immune response. On the other 
hand, immunotherapy is rising as promising alternative to the conventional 
chemotherapeutic approach, albeit a significant proportion of patients do not respond to 
these treatments for still unknown reasons. The metabolic interplay between tumour and 
immune cells might provide the knowledge required for the development of combined 
therapies aimed at increasing immunotherapy effectiveness.  
 
2.4 Targeting of metabolic pathways for cancer therapy 
 
The altered tumour metabolism has been recognized as a specific hallmark of cancer [1]. 
Given its crucial role in determining cancer development and progression, tumour 
metabolism has been targeted by different approaches, as an alternative strategy to the 
more conventional chemotherapy. Classical antineoplastic drugs exert their anti-tumour 
functions essentially by targeting the enhanced proliferation typically associated with tumour 
cells. However, in many tumour settings chemotherapeutic drugs fail to restrict tumour 
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growth, due to intrinsic tumour resistance or to selection of resistant clones induced by the 
drug itself [109]. It is therefore essential to develop treatments to overcome the intrinsic or 
acquired tumour resistance to therapeutic treatments. To this purpose, tumour metabolism 
has emerged as a promising target, allowing for the generation of several inhibitors that 
selectively regulate altered metabolic pathways of cancer cells [110].  
Numerous metabolic pathways have been successfully targeted in preclinical settings and 
have led to promising results. However, their translation into the clinical practice has been 
discontinuous. Beside the already discussed rationale of targeting glycolysis, other crucial 
bioenergetic and biosynthetic pathways have been considered in drug development [92]. 
For instance, nucleotide, amino acid and lipid biosynthesis can be suppressed in cancer 
cells, by developing selective inhibitors of rate-limiting enzymes. Oncometabolite production 
and secretion are other tumour-specific pathways that have been targeted in metabolism-
targeted anti-tumour therapies. Of note, chemical inhibitors of the Monocarboxylate 
transporters MCT1 and MCT2 (involved in lactate uptake) and of MCT4 (responsible for 
lactate secretion) and lactate dehydrogenase (LDH) (the enzyme involved in lactate 
production) are in clinical or preclinical evaluation for cancer treatment [111, 112].  
A relevant improvement in cancer treatment could be represented by combination therapies 
able to compensate the drawbacks of single therapies. Immunotherapies are experiencing 
an explosive growth; however, major concerns regarding the inter-patient variability, in terms 
of therapy response, have been raised [113]. Moreover, accurate prediction of response to 
therapy is still missing, meaning that other unknown factors are involved in determining 
immunotherapy responsiveness. To this end, the interplay between tumour metabolism and 
immune cells might result critical for the combination of metabolism-targeting therapies and 
immunotherapies [109].  
In last decade the concept that also immune cells undergo metabolic adaptation during the 
phases of the immune response is emerging. Adaptive immune cells modify their metabolic 
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requirements during the differentiation process. Naïve T cells rely mostly on OXPHOS of 
fatty acids to produce ATP, and gradually switch toward a glycolytic phenotype when 
becoming effector T cells [114]. During the T cell activation phase, together with the 
differentiation in effector T cells, also a memory compartment is generated. Memory T cells 
exhibit an intermediate metabolic phenotype, characterized by OXPHOS, similarly to naïve 
cells, and a reduced glucose dependency compared to terminally differentiated effector T 
cells [115, 116]. The differentiation status of T cells has been reported to be crucial in a 
therapeutic prospective. Undifferentiated memory T cells show superior ability in conferring 
tumour protection in adoptive cell transfer settings [117, 118]. This has generated a growing 
interest in developing methods able to expand memory T cell subsets [119-122]. Such 
studies have effectively produced long-lived memory T cells by exposing naïve cells to 
homeostatic cytokines, by interrupting the normal differentiation process, or by regulation of 
the TCR signalling pathway. In addition, targeting the glycolytic pathway has been 
demonstrated to efficiently modulate the differentiation process of T cells. Enhancing 
glycolysis in activated CD8 T cells leads to the generation of terminally differentiated effector 
cells, while glycolysis inhibition favours the formation of long-lived memory T cells [123]. 
Deciphering the key factors that regulate T cell differentiation is mandatory to improve anti-
tumour immunotherapeutic approaches. In this view, an accurate characterization of the 
metabolic requirements of immune cells in the tumour microenvironment could shed light on 
this fundamental aspect of T cell biology. 
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AIM of the STUDY 
 
 
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, characterized 
by a dismal survival. Conventional anticancer treatments are ineffective in controlling PDAC 
progression, posing the urgent need for novel therapeutic strategies. Immunotherapy has 
been largely explored as a promising anticancer approach but not convincingly introduced 
yet for this tumour type, and, furthermore, the comprehension of the mechanisms that lead 
to a successful immunotherapeutic strategy is still incomplete. In this thesis, the PDAC 
microenvironment has been thoroughly investigated, in order to delineate key features of 
immunologic and tumour components involved in the spontaneous anticancer immune 
response. These results could contribute to a better understanding of the microenvironment 
of human PDAC and foster the introduction in clinical practice of immunotherapeutic 
strategies in PDAC. 
Tertiary lymphoid tissue (TLT) has been demonstrated to coordinate adaptive immune cell 
activation against cancer in several tumour settings. This thesis was designed to investigate 
TLT occurrence in PDAC, evaluating its role in cancer progression. Cancer cell metabolism 
has been recently demonstrated to influence tumour progression directly and by acting on 
tumour infiltrating immune cells (TILs). Here, the metabolism of pancreatic cancer cells has 
been investigated focusing on its impact on the phenotype and function of TILs.   
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METHODS 
 
Patients and study design 
 
The study included two Cohort of patients. Cohort 1 included 104 patients, aged older than 
18 years, diagnosed with pancreatic ductal adenocarcinoma (PDAC) and who consecutively 
underwent surgery at the Humanitas Clinical and Research Centre, from February 2010 to 
December 2012. Clinicians prospectively assembled a clinical retrospective database by 
collecting patient demographics, clinical and histo-pathological data, as detailed in Table 2.  
Investigators who performed the assessment of immune variables were blinded to the 
clinical data. Patients with metastases at surgery (n=7) were excluded from the analysis. 
Detection of postsurgical local and distant tumour recurrences included a baseline thoracic 
and abdominal computed tomography (CT) and CA19-9 serum level evaluation. CT was 
repeated every 3 months during the first 2 years after surgery, and every 6 months 
afterward. CA19.9 assessment was repeated on a monthly basis during chemotherapy and 
concomitantly to CT scan afterward. As outcome variable we considered disease-specific 
survival (DSS), defined as any PDAC-related death detected in the observational period 
beginning immediately after surgery. Patients who died from causes other than PDAC were 
considered as lost to follow-up. The time of DSS was calculated from the date of surgery 
until date of death. The mean follow-up was 563.4 days (Standard Deviation=320.8 days).  
Cohort 2 comprised 40 patients aged older than 18 years, from which pancreatic juice was 
withdrawn during pancreasectomy. Patients were diagnosed postoperatively with pancreatic 
adenocarcinoma (n=31), pancreatitis (n=2), papillary tumours (n=4), neuroendocrine tumors 
(n=2), IPMN (n=1) (Table 3). Cohort 3 included 18 patients (Table 4). Clinicians 
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prospectively assembled a clinical retrospective database by collecting patient 
demographics, clinical, and histopathological data, as detailed in Tables 3 and 4. All the 
patients were enrolled in the study after signed informed consent including collection of 
biological specimens and clinical data. The study was approved by the Ethical Committee 
of the Institution (protocol number ICH-595, approval issued on May 2009).  
 
Table 2. Summary of clinical and immunological variables of Cohort 1 patients. COX 
regression analysis (a). Densities as percent immune-reactive area at the tumor-stroma 
interface (b). Age was entered as continuous variable.   dG1/G2, well-to moderately 
differentiated; G3, G4 poorly differentiated (c). R0, microscopic radical resection; R1, 
microscopic non-radical resection (e). “Ref” (reference): refers to the reference group used 
to calculate the p-value. 
  
	
 
 
           CD20-TLT a, b  CD20-TILsa, b  CD8-TILsa, b 
 n (%)  median P  median P  median P 
           
All cases 104 (100)  3.72   0.41   0.61  
             
Patient demographics            
             
Age (years)c 
 104 (100)  - 0,170  - 0.086  - 0.432 
             
Gender 
Female 54 (51.9)  3.90 Ref  0.38 Ref  0,61 Ref 
Male 50 (48.1)  3.35 0.464  0.44 0.686  0.60 0.502 
             
Tumor features            
Nodal 
involvement 
No 35 (33.6)  3.14 Ref  0,38 Ref  0,44 
Ref 
 
Yes 67 (64.4)  4.31 0.857  0.45 0.325  0.64 0.187 
             
Local 
Invasion 
pT1-pT2 11 (10.6)  3.68 Ref 
 
0,32 Ref  0,41 Ref 
pT3-pT4 91 (87.5)  4.02 0.431 0,43 0.456  0.61 0.375 
             
Grade d 
G1/ 
G2 
47 (45.2)  4.17 Ref 
 
0.38 Ref  0.57 Ref 
G3/ 
G4 
44 (42.3)  3.53 0.351 0.47 0.816  0.64 0.930 
             
Chemotherapy (CTX)            
Adjuvant 
No 35 (33.7)  3.83 Ref  0.36 Ref  0.64 Ref 
Yes 69 (66.3)  3.56 0.937  0.43 0.575  0.57 0.310 
             
Neo- 
Adjuvant 
No 90 (86.5)  4.02 Ref  0.41 Ref  0.63 Ref 
Yes 14 (13.5)  2.01 0.200  0.42 0.848  0.39 0.287 
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  N (%) 
Patient Age ≤70 yrs 
>70 yrs 
22 (55%) 
18 (45%) 
   
Patient Gender Male 
Female 
20 (50%) 
20 (50%) 
   
Diagnosis Ductal 
Adenocarcinoma 
Pancreatitis 
Papillary-Ampulla 
Neuroendocrine 
IPMN 
31 (77.5%) 
2 (5%) 
4 (10%) 
2 (5%) 
1 (2.5%) 
  
   
Tumour invasion* 
 
pT1/pT2 
pT3/pT4 
 
11 (31%) 
25 (69%) 
 
   
Nodal Status* 
 
N0 
N1 
N2 
10 (28%) 
19 (53%) 
5 (19%) 
   
Tumour Grade* 
 
G1/G2 
G3/G4 
24 (65%) 
13 (35%) 
* Data refer only to tumour patients  
Table 3. Summary of the clinical features relative to Cohort 2 patients. 
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  N (%) 
Patient Age ≤70 yrs 
>70 yrs 
14 (78%) 
4 (22%) 
   
Patient Gender Male 
Female 
9 (50%) 
9 (50%) 
   
Tumour invasion pT1/pT2 
pT3 /pT4 
0 (0%) 
18 (100%) 
   
Nodal Status N0 
N1 
N2 
4 (22%) 
14 (78%) 
0 (0%) 
   
Tumour Grade G1/G2 
G3/G4 
7 (39%) 
11 (61%) 
 
Table 4. Summary of the clinical features relative to Cohort 3 patients. 
 
Immunohistochemistry  
2μm thick tissue slides from formalin processed and paraffin-embedded tumour sections 
were processed for immunohistochemistry. After deparaffinization and rehydration, sections 
were immersed in a water bath for antigen retrieval, and then incubated with 3% H2O2 for 
15 minutes. Slides were autostained (IntelliPATH FLX, Biocare Medical) with primary 
antibodies raised against CD20 (DAKO, L26), CD8 (DAKO, C8/144B), CD68 (DAKO, KP1) 
and CD3 (DAKO, F7.2.38), or manually stained  with antibodies against PD-1 (Abcam 
NAT105), DC-Lamp (Dendritics, 1010E1.01), PNAd (BD Pharmingen, MECA-79), Lyve-1 
(Abcam, polyclonal), CXCL13 (R&D, polyclonal), CCL21 (R&D, polyclonal), Ki67 (DAKO, 
MIB-1), Bcl-6 (DAKO, PG-B6p), GLUT-1 (Abcam, clone EPR3015). This was followed by a 
30-minute incubation with the DAKO Envision system (Dako) or Anti-Goat Polymer kit 
(Biocare). Brown colour was obtained using diaminobenzidine tetrahydrochloride (DAB) 
(Dako) as chromogen. Nuclei were lightly counterstained with a freshly made haematoxylin 
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solution (Medite). The sections were further washed in water, mounted and analysed under 
an optical microscopy.  
 
Image analysis 
After staining procedure, tissue sections were digitalized using a slide digital scanner 
(Olympus dotSlide). At least two independent operators blinded to any patient clinical data 
selected three non-overlapping and non-contiguous areas comprising of approximately 50% 
of tumour and 50% of stromal tissue and including CD68+, CD20+, CD8+ or PD1+ cells 
(Figure IRA, A). For CD20-TLT analysis, 3 non-contiguous fields were chosen representing 
the entire CD20 positive area within the TLT, regardless of the location in the tumour or in 
the stroma. When stained for CD20, TLT displayed a typical structure that can be recognized 
by operators. 
Both sampled microscopic area and light density were maintained fixed throughout the 
analysis. Selected areas were quantified by computer-assisted image analysis, with ad hoc 
software, to obtain the percentage of immune reactive areas (IRA%) of the digitalized tissue 
surface (Figure IRA, B-C).  
 
Figure IRA%. Computer-assisted image analysis workflow. Representative image of the 
three selected areas. Dashed line delimitates tumour tissue from stromal region (A). 
Discrimination of positive signal (red) from background signal (yellow) obtained by software 
analysis (B). Scatter dot-plot of IRA% values obtained from analysis of pictures; red line 
represents median (C). 
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The variable PD1-GC was expressed as a dichotomous value, assigning a positive value 
when PD1 positive cells were present in the germinal centre of previously assessed CD20-
TLT. The extent of the overall distribution of CD20-TLT, CD20-TIL, CD8-TIL, CD68-TAMs, 
GLUT-1 and PD1-TILs IRA%, expressed as continuous variables, and PD1-GC score were 
used to perform statistical analyses. For each immune variable with continuous values 
(CD20-TLT, CD20-TILs, CD8-TILs), we stratified patients by grouping into quartiles. 
 
Gene expression analysis 
Patients were divided into TLThi (4th quartile n=5) and TILshi (4th quartile n=5), according to 
CD20-TLT and CD20-TIL IRA% values and RNA was extracted from FFPE tissues using 
the RNeasy FFPE kit (QIAGEN); adjacent normal pancreatic tissue (n=5) was used as a 
control. RNA from Panc02 tumours was extracted after collagenase (Sigma Aldrich) 
digestion of tumour fragments and isolation of the leukocyte fraction by gradient 
centrifugation (Percoll (GE Healthcare life sciences)). Cells were re-suspended with 
PureZOL (Bio-Rad), and RNA was purified using RNeasy Plus Mini kit (QIAGEN) following 
manufacturer instructions. In each case, cDNA was obtained after an 8-cycle pre-
amplification step, followed by reverse transcription with the RT2 PreAMP cDNA synthesis 
kit (Qiagen). For CD45+ cells from Panc02 murine models, pre-amplification step was not 
necessary, cells were isolated from anti-PD1 treated sh-PFK and sh-SCR tumors using the 
CD45 (TIL) MicroBeads, mouse kit (Miltenyi biotec). RNA was extracted with PureZOL (Bio-
Rad), purified with RNeasy Plus Mini kit (QIAGEN) from both CD45+ fraction and from CD45 
negative flow through, and reverse transcription performed with the RT2 cDNA synthesis kit 
(Qiagen). Real-Time PCR was performed using commercially available PCR Arrays (RT2 
ProfilerTM PCR Array System, Qiagen), on a ViiA™ 7 Real-Time PCR (Life Technologies). 
Differences in gene expression were analysed by the comparative threshold cycle (Ct) 
method with DataAssistTM (Life Technologies), after global normalization. Within PDAC 
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patients groups, samples with the lowest Ct variability (n=3) were selected for analysis. 
Hierarchical clustering was performed with the Cluster 3.0 software, including the whole 
gene-list available in the Array. The normalized signal value was adjusted to log transform 
data and “median” was selected to centre genes. Clustering was performed using the 
Pearson correlation function with Java TreeView and exported to heatmap images.  
For the network analysis, uploading control and α–CD20-treated data set, containing gene 
identifiers and corresponding expression values, into the Ingenuity Pathways Analysis 
application generated significant pathways and molecular networks. The resulting Network 
Eligible molecules were overlaid onto a global molecular network based on the in Ingenuity’s 
Knowledge Base (Ingenuity® Systems, www.ingenuity.com), a uniquely structured 
repository of biological and chemical “findings” curated from various sources including the 
literature. The Functional Analysis of the network identified the biological functions most 
significant to the molecules in the network including the whole gene-list available in the 
Array.  
 
PDAC murine models 
All mice used for the orthotopic implantation of Panc02 cells were 8-week-old C57BL/6J 
females purchased from Charles River (Calco, Italy) and housed in a specific pathogen–free 
animal facility of the Humanitas Clinical and Research Centre, in individually ventilated 
cages. Procedures involving mice and their care were conformed to EU and Institutional 
Guidelines, and approved by the Italian Ministry of Health (project 5/2015). Murine Panc02 
cell line was kindly provided by Dr. Piemonti (San Raffaele Hospital, Milan) and cultured in 
RPMI 1640 medium (Lonza) supplemented with 10% FBS, 2mM l-Glutamine. Cells were 
cultured in a humidified incubator with 5% CO2, for one passage before in vivo injection. 
Mice were kept anesthetized during all surgical operation by intraperitoneal administration 
of a ketamine and xylazine solution. The stomach and the adherent pancreas were 
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exteriorized to expose the head of the pancreas, in which 30μl of 106 Panc02 cells 
suspension was injected using a 30-gauge insulin needle. All the organs were then returned 
to their original position and peritoneum and skin were sutured. Animals were randomized 
after surgery into two treatment groups, the first receiving 250μg of α–CD20 antibody 
(Genentech, clone 5D2), and the second receiving 250μg of the isotype-matched (IgG2a) 
irrelevant immunoglobulin (BioXCell C1.18.4), both by i.p. injection 3 days after surgery. 
After 3 weeks from surgery, mice were sacrificed and tumour masses collected. Single cell 
suspensions were obtained by incubating fragmented tumours with 0.5 mg/ml of clostridium 
histolyticum-derived collagenase (Sigma Aldrich) for 30 minutes at 37°C. Cells were then 
washed and tumour infiltrating leukocytes purified by a 44%/66% Percoll (GE Healthcare 
life sciences) gradient centrifugation. The purified leukocytes were washed and aliquoted 
for multi-colour FACS analysis or RNA extraction. Alternatively, tissues were fixed for 
immunohistochemical analysis. 
Pancreatic cancer–prone LSL-KrasG12D-Pdx1-Cre mice (KC mice) were bred, maintained 
and treated at the saprophytic and pathogen-free animal facility of the Molecular 
Biotechnologies Centre (Torino, Italy), as previously described [124]. Briefly KC mice were 
vaccinated at 32 weeks of age and every 3 weeks for a total of 3 rounds of vaccination. 
Vaccination was achieved by electroporation of femoral muscle with 50μg of plasmid (either 
mock pVAX vector or the human Enolase (ENO1) encoding vector). Mice of the same age 
were randomly assigned to control and treatment groups, and all groups were specifically 
treated concurrently. Mice were sacrificed 2 weeks after the last vaccination to perform 
histologic or immunohistochemical analyses. Splenocytes were analysed for the ability to 
secrete IFN-γ in response to the recombinant ENO1 ex vivo as described in [124]. Briefly, 
anti-IFN-γ capture mAb (mIFN-γ kit by BD) was used to coat nitrocellulose plates (Millipore, 
Milan, Italy) by overnight incubation at 4 °C. T cells from spleens were stimulated with rENO1 
(10µg/ml), for 40 h at 37 °C and seeded at 3 x 105cells/well. All conditions were carried out 
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in quadruplicate. Plates were then analyzed following manufacturer’ instructions using AEC 
(Sigma-Aldrich) substrate, and spots quantified with the microplate reader along with a 
computer-assisted image analysis system (AID, Amplifon, Milan, Italy). The number of spots 
was calculated by subtracting the number of spots in medium only (background) from that 
in the presence of stimuli.  
Subcutaneous tumour models were obtained by injecting DT6606 or Panc02 cells. Murine 
DT6606 were derived from KC mice tumours and can be considered “early” tumour since 
they bear only one single mutation. Panc02 cells were originated from chemically induced 
tumour and harbor multiple mutations, therefore can be considered as a “late” lesion. Both 
cell lines were cultured in complete RPMI (RPMI 1640 medium (Lonza) supplemented with 
10% FBS (Euroclone), 2mM l-Glutamine (Lonza), and 100 units of Potassium Penicillin and 
100μg of Streptomycin Sulfate (Lonza) per 1ml of culture media). Cells were cultured in a 
humidified incubator with 5% CO2, for one passage before in vivo injection. Silenced cell 
lines sh-SCR and sh-PFK were generated as described in next paragraph of this section. 
Both cell lines were cultured in complete RPMI supplemented with Puromycin (Sigma 
Aldrich) 1µg/ml for two weeks before in vivo injection. For the immunotherapeutic protocol, 
animals were randomized after injection into two treatment groups, the first receiving 200μg 
of α–PD1 antibody (Bioxcell, clone RMP1-14), the second receiving 200μg of anti-
trinitrophenol isotype control (Bioxcell, clone 2A3), both with i.p. injections starting 7 days 
after surgery, every 3 days. At 3 weeks from surgery, mice were sacrificed, and tumor 
masses collected for subsequent analysis. All tumour growth curves were generated by 
measuring tumour dimensions with caliper. 
 
Lentiviral particles production and silencing validation 
Plasmids encoding sh-RNA against murine pfk-m and scramble sequence (targeting a non-
mammalian gene) were purchased from Sigma Aldrich (PFK-m: TRCN000012536; 
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Scramble: SHC002) as bacterial glycerol stocks. Both plasmids encode for Puromycin N-
Acetyltransferase enzyme, which allowed the negative selection of transduced cells. 
Bacterial culture was established inoculating a small amount of the glycerol stock into 200ml 
LB (GE healthcare) supplemented with Ampicillin (Sigma Aldrich) 50µg/ml, and incubated 
overnight at 37°C under vigorous shaking. Plasmidic DNA was extracted using MAXI-Prep 
kit (Promega) following manufacturer’s instructions.  
Lentiviral particles were produced by co-transfection of 293T cell line using sh-RNA 
encoding plasmid together with packaging (DR8.2) and envelope (VSV-G) plasmids (both 
from Addgene). Supernatants containing lentiviral particles were collected 48 hours after 
transfections, and directly used on Panc02 cells to generate sh-SCR and sh-PFK cell lines. 
1ml of supernatant was added to Panc02 cells cultured in 6-well plates when 50% of 
confluence was reached, and culture was immediately centrifuged at 300g for 1 hour. Then 
2ml of fresh complete RPMI was added and cells incubated at 37°C overnight. Medium was 
replaced with fresh complete RPMI supplemented with 1µg/ml Puromycin (Sigma Aldrich) 
and maintained for two weeks before using cells in an in vivo experiment. During selection, 
mRNA was extracted from cells and tested to determine gene silencing of pfk-m as shown 
in graph Fig. 4.8 B. 
 
Flow-cytometry 
Absolute numbers of CD19+, CD3+, CD11b+ cells were assessed by flow cytometry on 
peripheral blood leukocytes at day 0, 3, 7, 14 and 21 days from antibody injection. Trucount 
kit (BD Biosciences) was used to obtain absolute numbers. Tumor digests were analysed 
using the following fluorophore-conjugated primary antibodies: anti-CD45 (BD Pharmingen 
30-F11), anti-CD19 (eBiosciences eBio1D3), anti-CD3 (eBiosciences 145-2C11), anti-
CD11b (BioLegend M1/70), anti-CD8 (BioLegend 53-6.7), anti-PD1 (Biolegend, clone 
29F.1A12). Zombie Aqua (Biolegend) amine-reactive fluorescent dye was used to perform 
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dead cell exclusion. 2-NDBG uptake was measured by incubating digested tumors in a 
200µM 2-NBDG (Sigma Aldrich) solution (phosphate buffer saline, PBS) for 30 minutes at 
37°C. Sample acquisition was performed on a BD LSRFORTESSA (BD Biosciences) and 
data analysed with FlowJo software. 
 
Glucose uptake in vitro and image analysis 
Panc02 and DT6606 cell lines were cultured in 48-well plate using complete RPMI until 70% 
confluence was reached. Cells were incubated in a 200µM 2-NBDG (Sigma Aldrich) solution 
(PBS) for 30 minutes at 37°C, washed and maintained in PBS during acquisition. Differential 
interference contrast (DIC) and fluorescent images were obtained with CellR wide field 
microscope (Olympus). Cells were seeded in three wells and a single wide field image per 
well was acquired (20X objective). DIC and FITC images were collected for each condition 
and analyzed using Fiji open-source software. Analysis was performed selecting single cells 
as region of interest (ROI) and measuring the mean fluorescent intensity (MFI) in FITC 
channel. At least 20 ROIs were measured in each well, and three wells were analyzed for 
both Panc02 and DT6606 cell lines. 
 
Pancreatic juice collection and preparation 
Pancreatic juice was collected intraoperatively in a vial containing anticoagulant and stored 
at 4°C until transportation to the laboratory for processing. Once in the laboratory, the 
sample was centrifuged within 5 hours of collection, aliquoted in EDTA-containing vials and 
stored at -80°C. Patients had been fasting overnight. 
 
Nuclear magnetic resonance (NMR) spectroscopy 
180μL of pancreatic juice were mixed with 20μL of D2O buffer (1.5M KH2PO4 dissolved in 
99.9% D2O, pH 7.4, 2mM sodium azide and 0,1% 3-(trimethyl-silyl) propionic acid-d4 
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(TSP)). A total of 200μl of this mixture was transferred into a 3-mm NMR tube (Bruker 
BioSpin) for the analysis. NMR spectra of pancreatic juice samples were acquired using a 
Bruker IVDr 600MHz spectrometer (Bruker BioSpin) operating at 600.13MHz proton Larmor 
frequency, equipped with a 5mm PATXI H/C/N with 2H-decoupling probe including a z axis 
gradient coil, an automatic tuning-matching (ATM) and an automatic refrigerated sample 
changer (SampleJet). Temperature was regulated to 300 ± 0.1K with a BTO 2000 
thermocouple. 
 
Multivariate statistical analysis applied to metabolite quantification by NMR 
All multivariate and univariate analyses regarding the NMR-based metabolomics study were 
performed by PLS_Toolbox 8.2.1 and homemade scripts, respectively, in Matlab 2016a 
programming environment.  Metabolites signals deconvolution and integration was 
accomplished by an in-house developed software in MATLAB programming suited by Dr. 
P.G. Takis.  The algorithm is based upon the unconstrained non-linear minimization (fitting) 
of the metabolite NMR signals, employing a combination of lorentzian-gaussian functions.  
By this approach, each NMR region of interest is decomposed and deconvoluted into its 
component parts, and then integrated to obtain the metabolite concentrations in arbitrary 
units. For the n x Fold concentration changes for each metabolite the following equation was 
employed: 
𝑛	 × 	𝐹𝑜𝑙𝑑 = 𝑙𝑜𝑔* +𝑚𝑒𝑑𝑖𝑎𝑛	𝑜𝑓	𝑔𝑟𝑜𝑢𝑝	1𝑚𝑒𝑑𝑖𝑎𝑛	𝑜𝑓	𝑔𝑟𝑜𝑢𝑝	26 
 
Optical imaging 
In vivo evaluation of glucose uptake was assessed using the fluorescent glucose analogue 
XenoLight RediJect 2-DG-750 probe (Perkin Elmer), following datasheet instructions. 
Imaging was performed ex vivo on excised tumors after 24 hours from i.v. injection of the 
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probe, using the IVIS Lumina III InVivo Imaging System (Perkin Elmer). The acquisition was 
performed using four filter pairs in order to calculate spectral unmixing. Emission was 
collected with a 790nm filter, while excitation was performed with four excitation filters (680, 
700, 720, and 750nm). Binning value: 8; f/Stop: 2. Images were analyzed with Living Image 
4.3.1 software (Perkin Elmer). 
 
Statistical analysis  
The associations between values of immune cells and other features concerning patient 
clinical conditions were estimated by Pearson simple linear regression analysis. A 
multivariate Cox proportional hazards model was developed to assess the role of immune 
variable density and demographic, clinical, and histo-pathologic features, in predicting the 
outcome of disease speciﬁc survival. Cox multivariate analysis was performed by entering 
variables with a P value lower than 0.05 at univariate analysis. Kaplan–Meier curves of DSS 
were plotted and the log-rank test was used to compare the curves of each subgroup of 
patients with pancreatic cancer. The use of quartiles as opposed to median is justified by 
the fact that prognostic effect of TLT was significant only for extremly low values of IRA% 
(1st quartile), whilst this was not the case for median values (data not shown). The second 
and third quartiles showed a trend towards a better prognosis, even if not significant, thus 
justifying their grouping with the fourth quartile. Biologically, this result suggests that TLT 
occurrence seems to be generally favourable, except for patients with very low density (1st 
quartile). The correlation between IRA% values of GLUT-1 and PD-1 were estimated by 
nonparametric Spearman Rank correlation coefficient test and linear regression analysis. 
Differences between groups were estimated by non-parametric Mann Whitney U test. When 
more than one variable was evaluated, two-way ANOVA test was used and P values 
calculated by Tukey’s multiple comparisons post-test. In each experiment, sample size was 
at least 9 mice for each group. For each test, only two-sided P values lower than 0.05 were 
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considered statistically signiﬁcant. All the analyses were done using SPSS (Version 22.0) 
and GraphPad Prism software (Version 4.1). To study the prognostic value of immune 
variables, we adhered to “Reporting Recommendations for Tumour Marker Prognostic 
Studies (REMARK)” [125] for high quality of tumour marker studies. 
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have been performed by Dr. Takis P. G. at Giotto Biotech s.r.l.. 
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RESULTS 
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3. B cell duality in 
pancreatic cancer 
  
	 44	
3.1 Background and goal 
 
In some tumour conditions, priming of antigen-specific T cells can occur extra-nodally in 
peripheral tissues, within lymph node-like tertiary lymphoid tissue (TLT) [37]. During the first 
two years of my project, I have investigated the occurrence of TLT in human pancreatic 
adenocarcinoma (PDAC), one of the most aggressive human malignancies with a dismal 
survival rate at 5 years [126]. Clinically, PDAC is characterized by low responsiveness to 
conventional chemotherapy treatments. This feature has fostered the identification of 
biomarkers to better stratify tumour patients and choose the optimal therapeutic treatment 
accordingly. Among others, immune mediators have shown to be critical indicators of 
patients’ prognosis in multiple tumour types, including PDAC. Despite the advent of 
innovative prognostic tools, histo-pathological examination of immune cells in tumours still 
stands as one of the most powerful approaches to assess their relevance in patients’ 
prognosis. This approach has allowed us to appreciate important features of immune cells 
related to their distribution in the tumour tissue. 
Spatial compartmentalization of T and B lymphocytes within TLT is crucial for recruitment of 
tumour infiltrating T lymphocytes (TILs) [127], T cell activation and germinal centre reactions, 
and has been shown to coordinate with TILs infiltration in predicting better clinical outcome 
[127]. After a preliminary characterization of TLT, we have moved to a more specific analysis 
of B cells within tertiary lymphoid structures.  
B cells play a dual role in cancer progression: while they critically regulate T- cell activation 
[28], a function highly favoured by the presence of an immune site like TLT, they also release 
immunosuppressive molecules with the ability to foster cancer development [128]. During 
the analysis of TLT in human sections, we noticed that B cells localized in two distinct 
compartments, either scattered in the tumour tissue (B-TILs) or strategically located in 
association with T cells, within organized lymphoid tissue (B-TLT). Considering the different 
microenvironment the two B-cell components are exposed to, we hypothesized that they 
	 45	
could exert distinct functions, thus we focused on the duality of this cell population. 
These were the main objectives: 
• To evaluate the infiltration of B cells in human PDAC specimens. 
• To investigate the clinical relevance of B cells in human PDAC according to their 
spatial distribution in the microenvironment. 
• To define the immune features of the tumour microenvironment associated to B cells. 
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3.2 Occurrence and characterization of TLT in human PDAC  
 
By staining PDAC tissue specimens with anti-CD3 and anti-CD20 antibodies, we 
appreciated the presence of organized lymphocyte aggregates, mainly localized in the 
tumour stroma. As previously said, TLT resembles secondary lymphoid organs, since they 
share the main cellular and molecular components (Figure 3.1).  
 
Figure 3.1. Characterization of TLT in human PDAC. In human PDAC tissue specimens, 
we identified organized lymphoid tissue in the stromal region, composed of 
compartmentalized B and T cell areas (A and B) and mature dendritic cells (C). Scale bars: 
500µm (A and B); 200µm (C).  
 
 
These structures are not present in the normal pancreatic tissue, thus suggesting that their 
neo-genesis is related to tumour occurrence. A more detailed characterization of B cell 
aggregates revealed the presence of distinct B cell (Figure 3.1, panel A) and T cell 
compartmentalized areas (Figure 3.1, panel B), containing mature dendritic cells 
expressing DC-LAMP (Figure 3.1, panel C) and PNAd+ high endothelial venules (HEV) 
(Figure 3.2, panel A), thus confirming that they have features of tertiary lymphoid tissue 
(TLT).  
 
 
Figure 3.2. TLT in human PDAC is equipped to mediate recruitment of naïve 
lymphocytes. We confirmed the presence of high endothelial venules (HEV), expressing 
PNAd (A), essential for naïve T-cell recruitment and the presence of the two chemokines 
CXCL13 and CCL21 fundamental for the maintenance of TLT compartmentalization through 
recruitment of B and T cells (B and C). Scale bars: 200µm. 
!
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The presence within lymphoid tissue, of the lymphorganogenic chemokines CXCL13 
(Figure 3.2, panel B) and CCL21 (Figure 3.2, panel C), involved in recruitment of B and T 
cells, suggests an important immunological role for TLT in the recruitment of tumour 
infiltrating lymphocytes in human PDAC, also confirmed by the presence of Lyve-1 positive 
lymphatic vessels (Figure 3.3, panel A). B cell area was often found to contain a germinal 
centre expressing both the proliferation markers Ki67 (Figure 3.3, panel B) and Bcl-6 
(Figure 3.3, panel C), suggesting that this immune site is fully equipped to sustain B cell 
activation in human PDAC. 
 
Figure 3.3 Functionality of TLT in human PDAC. We documented the presence of Lyve-
1+ lymphatic vessels (A), suggesting the possibility of draining tumour antigens; Ki67+ 
proliferating cells (B), an important feature that could indicate the presence of a germinal 
centre; and Bcl-6, expressed by activated B cells (C). Scale bars: 500µm A-C; 50µm insert 
in A. 
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3.3 Distinct spatial distribution of B cells in human PDAC 
 
By analysing the occurrence of TLT in human PDAC specimens, we observed that B cells 
and T cells localize both within and outside such structures. We decided to focus on B cells, 
because their dual localization could represent an important feature related to their function. 
Compared to normal pancreas (Figure 3.4, A), immunohistochemical analysis of human 
PDAC specimens with an anti-CD20 antibody revealed a considerable infiltration of CD20+ 
B lymphocytes (Figure 3.4, B-D). As already mentioned, CD20+ cells were found both as 
irregularly interspersed cells at the tumour-stroma interface (CD20-TILs) (arrowheads in 
Figure 3.4, B and C), but also as dense aggregates, displaying a distinct spatial 
organization, located within the tumour stroma (asterisks in Figure 3.4, panel B and D). In 
order to describe the spatial distribution of B cells in PDAC we compared the IRA% of CD20+ 
cells (Figure 3.4, E), focusing on B cell aggregates (CD20-TLT) or infiltrating the tumour-
stroma interface (CD20-TILs). This analysis shows that in human PDAC, B cells are 
preferentially organized in TLT rather than randomly distributed in the tumour tissue. 
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Figure 3.4. B cells strategically localize in tertiary lymphoid tissue in human 
pancreatic adenocarcinoma. Representative images obtained from virtual digital slides of 
human normal pancreas (A) and pancreatic cancer (B and D), stained for CD20+ B cells. 
Staining with an anti-CD20 antibody shows a few B cells scattered in a normal pancreas 
(arrowhead in A) and at the tumour stroma-interface in PDAC (arrowheads in C), while the 
majority of B cells is located within dense aggregates (asterisks in B and D). Quantitative 
evaluation of the density of B cells according to their localization within CD20-TLT or as 
CD20-TILs in tissue specimens from 104 PDAC patients (E). Scale bars: 1mm (A and B); 
500µm (C and D). Red lines represent mean; p-value calculated by Student’s t test ****: 
p<0,0001 (E). 
 
 
3.4 Dichotomy of B cell prognostic impact in human PDAC 
 
I next asked whether the dual pattern of B-cell infiltration within pancreatic tissue reflects a 
distinct prognostic value. Therefore, the clinical significance of B cells in human PDAC was 
assessed considering CD20-TLT and CD20-TILs as two distinct populations. In a 
retrospective study, I have quantitatively evaluated the percentage of immune-reactive area 
(IRA%) of the CD20-TLT and CD20-TILs at the tumour-stroma interface, in 104 tissue 
specimens from consecutive, non-metastatic PDAC patients (Table 2). CD20-TLT immuno-
reactive area (IRA%) ranged from <0.05% to 23.49%, with a median value of 3.72% 
(second–third quartiles, 1.71%-5.71%), while CD20-TIL IRA% ranged from <0.05% to 
1.89%, median value 0.41% (second-third quartile 0.26%-0.69%) (Table 2). We recorded 
38 events of disease specific death (DSS) in 104 PDAC patients, during the follow-up period 
of the study. Cox multivariate analysis showed that nodal status and grade associated to 
prognosis; notably, among the immune variables analyzed, B cells were independently 
associated to prognosis, but their prognostic value diverged according to their spatial 
distribution in the tissue. CD20-TLT associated with better prognosis (OR=0.24; 95% CI 
(0.08-0.71); P=0.010, 4th versus 1st quartile; Table 5), while CD20-TILs associated to worse 
prognosis (OR=2.56; 95% CI (0.91-7.23); P=0.07, 3rd versus 1st quartile; Table 5). This 
result highlights B cells as prognostic variables in human PDAC and suggests that the 
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influence of B cells on tumor progression changes whether they are confined within lymphoid 
tissue or are scattered at the tumour-stroma interface. Kaplan-Meier survival analysis 
showed that only high density of CD20-TLT (2nd-4th quartiles versus 1st) correlated with a 
better prognosis (median survival 16.9 mo CD20-TLThi versus 10.7 mo CD20-TLTlo; 
P=0.0085; n=104; Figure 3.5, panel A), while high CD20-TIL density (3rd-4th versus 1st-2nd) 
had a propensity to associate to worse prognosis but not significantly (median survival 12.7 
mo CD20-TILshi versus 18.9 mo CD20-TILslo; P=0.115; n=104; Figure 3.5, panel B). When 
the two variables were considered concomitantly, the immune signature comprising CD20-
TLThi /CD20-TILlo robustly predicted longer survival (median survival 30.9 mo CD20-
TLThi/CD20TILslo versus 14.1 mo any other; P=0.0051; n=104; Figure 3.5, panel C). This 
confirmed that the spatial distribution of B cells dictates their prognostic behaviour, and 
suggested that only B cells sequestered within a lymphoid tissue contrast tumour 
progression. 
 
 
Figure 3.5. B cell spatial organization impacts on human PDAC prognosis. Distinct 
spatial localization of B cells in the tumour microenvironment dictates their prognostic 
behaviour. Kaplan-Meier survival analysis shows correlation of longer disease specific 
survival (DSS) with high density of CD20-TLT (2nd-4th quartiles) (P=0.0085; n=104) (A), 
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while high density of CD20-TILs (3rd-4th quartiles) shows a tendency to associate to worse 
prognosis (P=0.115; n=104) (B). The immune signature comprising CD20-TLThi/CD20-
TILslo robustly predicts longer survival (P=0.0051; n=104) (C). P-value by Wilcoxon-Mantle 
Cox test.  
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Univariate  
Analysis a 
Multivariate  
Analysis a 
H.R. (95%C.I.) P H.R. (95%C.I.) P 
             Patient Demographics      
              
Age  
< 50 yrs 1.00 ref.    
50-70 yrs 2.13 (0.49-9.29) 0.312   
≥ 70 yrs 4.22 (0.98-18.13) 0.053   
              
Gender Female 1.00 ref.    Male 1.09 (0.58-2.07) 0.782   
       Tumor Features      
       
 Nodal 
involvement 
No 1.00 ref.  1.00 ref. 
Yes 2.13(1.03-4.41) 0.020 2.63 (1.17-5.90) 0.01
9 na     
       
Grade c G1/G2 1.00 ref.  1.00 ref.  G3/G4 2.74 (1.37-5.49) 0.004 2.50 (1.20-5.24) 0.015 
 
 
 
 
 
na     
      
Radical 
surgery 
No 1.96 (0.93-4.14) 0.078   
Yes 1.00 ref    
na     
              Chemotherapy (CTX)      
       Adjuvant 
treatment 
No 1.00 ref    
Yes 1.03 (0.52-2.04)   0.942   
        Tumor Immune features       
        
CD20-TLT 
(quartiles)b 
1st (0-1.71) 1.00 ref.  1.00 ref.  
2nd (1.71-3.72) 0.40 (0.16-0.98)     0.045 0.41 (0.15-1.09) 0.075 
3rd (3.72-5.71) 0.38 (0.16-0.94) 0.035 0.25 (0.09-0.72) 0.011 
4th (5.71-
23.49) 
0.40 (0.16-0.98) 0.044 0.26 (0.09-0.72) 0.010 
    
(0.
20-
0.9
4) 
  
CD20-TILs 
(quartiles)b 
1st (0-0.26) 1.00 ref.  1.00 ref.  
2nd (0.26-0.41) 1.30 (0.50-3.36) 0.594 1.49 (0.53-4.19) 0.449 
3rd (0.41-0.69) 2.88 (1.18-7.03) 0.020 2.85 (1.05-7.78) 0.040 
4th (0.69-1.89) 1.23 (0.46-3.30) 0.674 1.88 (0.58-6.03) 0.289 
    
(1.1
0-
5.90
) 
  
CD8-TILs 
(quartiles) b 
 
1st (0.0-0.34) 1.00 ref.    
2nd (0.34-0.61) 0.51 (0.22-1.23) 0.135   
3rd (0.61-1.15) 0.89 (0.39-2.07) 0.797   
4th (1.15-3.42) 0.69 (0.27-1.77) 0.445   
      
PD-1 GC 
Yes 1.00 ref.    
No 1.47 (0.72-2.99) 0.285 
  
  
a COX regression analysis  
b Densities as percent immunoreactive area at the tumor-stroma interface 
c G1/G2, well-to moderately differentiated; G3, G4 poorly differentiated  
 
Table 5. Predictors of post-surgical disease specific survival in cohort 1 patients with 
pancreatic ductal adenocarcinoma 
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3.5 Confinement of B cells within TLT associates to a germinal centre immune 
signature 
To understand whether the immune signature could be affected by the localization of B cells, 
I analysed the expression of immune related genes in the whole tissue section.  Since 
analysed specimens were of similar size, and were previously selected in the same tumour 
region (within resected tumour lesion), PDAC patients were selected exclusively using B cell 
infiltration. RNA was extracted from tumors displaying very high density of TLT (4th quartile; 
TLThi) and compared to tumours with very high density of TILs (4th quartile; TILshi). Non-
tumour pancreatic tissue was taken as control tissue (Normal).  PDAC specimens with high 
density of TLT showed major changes in genes related to germinal centre reaction 
(activation-induced cytidine deaminase (AICDA), B cell recent activation (CD27), B-cell 
signalling (B-cell linker (BLNK)), B-cell differentiation and proliferation (interleukin-7 (IL7) 
and interleukin-2 (IL2)) and B-cell responses (interleukin-13 (IL13)) (Figure 3.6). Notably, 
while TLThi PDAC samples exhibited a significant increase in genes related to T-cell 
infiltration (CD8B) and activation (IL-12), suggesting that the presence of B cells within TLT 
was also regulating T cell recruitment and activation, TILshi samples exhibited increased 
expression in immunosuppressive genes, including programmed cell death-1 ligand (PDL-
1 or CD274), CCR4 and transforming-growth factor-beta (TGF-β).  
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Figure 3.6 Heatmap showing the immune signature of human PDAC specimens with 
different CD20-TLT density. RNA was extracted from paraffin embedded tissue specimens 
of human PDAC, categorized as TLThi (n=3) or TILshi (n=3) after immunohistochemical 
evaluation with an anti-CD20 antibody. RNA from normal pancreata (n=3) was obtained as 
a control. Sample grouping followed the pattern of B cell distribution (i.e. TLThi versus TILshi 
samples segregating together), suggesting that B cell infiltration identifies specific gene 
expression programs. A z-score has been calculated for each gene. The color bar refers to 
increased scores (yellow) and decreased (blue), with intensity encoding magnitude. 
 
 
Immunohistochemical analysis confirmed that B cells within TLT were often engaged in a 
germinal centre reaction, as evidenced by Ki67 immunostaining (arrowheads in Figure 3.7, 
A) and B-cell lymphoma 6 protein (Bcl-6) (arrowhead in Figure 3.7, B). 
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Figure 3.7 Presence of germinal center in CD20-TLT. B cells within TLT are engaged in a 
germinal center reaction, as evidenced by Ki-67 (arrowheads in upper right panel) and Bcl6 
(arrowhead in lower right panel) staining within CD20-TLT (left panels). Sections 
represented in A or B are consecutive sections. Scale bars: 500µm and 200µm (insert in 
panel B). 
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3.6 Confinement of B cells within TLT correlates with CD8-TIL infiltration, and 
empowers their favourable prognostic value 
CD8+ T cells are an essential constituent of the antitumor immune response. In light of the 
association between TLT and CD8 in gene expression analysis, I assessed the density of 
tumour-infiltrating CD8+ T-cells (CD8-TILs) in cohort 1 PDAC patients. Notably, whole tissue 
visualization of CD8+ infiltrating cells evidenced a higher density of CD8-TILs in tissues with 
a high density of TLT (arrowheads in Figure 3.8, A). In fact, density of CD20-TLT correlated 
with the IRA% of CD8-TILs (r=0.29, P=0.009, n=104) (Figure 3.8, B), consistent with the 
ability of TLT to mediate recruitment of lymphocytes.  
 
 
Figure 3.8. Confinement of B cells within TLT correlates with CD8-TIL infiltration. (A-
B) CD20-TLT correlates with density of CD8+ T cells in human PDAC. Representative 
images of human PDAC specimens stained with an anti-CD8 antibody show a high density 
of CD8+ cells in tissues with TLT (A). Density of CD20-TLT (IRA%) linearly correlates with 
density of CD8-TILs (IRA%) (r=0.29, P=0.009, n=104) (B). Scale bars: 500µm. 
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While CD8-TILs were not associated to prognosis on their own (median survival 15.5 mo 
CD8-TILshi versus 14.2 mo CD8-TILslo; P=0.254, n=104) (Figure 3.9, A and Table 5), a 
concomitant high density of both CD8-TILs (2nd-4th quartiles) and CD20-TLT (2nd-4th 
quartiles) identified a subgroup of patients with better outcome compared to all other patient 
groups (median survival 17.9 mo CD20-TLThi/CD8-TILshi versus 12.2 mo CD20-TLTlo/CD8-
TILshi; P=0.031, n=104) (Figure 3.9, B), suggesting that the presence of tertiary lymphoid 
tissue empowers the prognostic function of CD8+ T cells. 
 
 
Figure 3.9. Confinement of B cells within TLT empowers the favourable prognostic 
value of CD8-TILs. Kaplan-Meier curves showing that while high density of CD8-TILs (2nd-
4th quartiles) is not significantly associated to prognosis (P=0.254, n=104) (A) concomitant 
high density of CD8-TILs (2nd-4th quartiles) and high density of CD20-TLT (2nd-4th quartiles) 
identifies a subgroup of patients with longer disease-specific survival (P=0.031; n=104) (B). 
Bars: 500 µm (A). 
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3.7 Characterization of intratumour TLT after antigen-specific 
immunotherapeutic vaccination in a preclinical model of PDAC 
The presence of immunologically active TLT could be of remarkable importance in the 
perspective of inducing a local antitumor immune response. I have therefore investigated 
whether an immunotherapeutic approach could induce formation of TLT in a genetic 
preclinical model of PDAC. This model is very suitable to recapitulate the microenvironment 
of PDAC, compared to subcutaneous models, although tumour development is slower. We 
took advantage of the collaboration with the group of Professor F. Novelli, at the University 
of Turin, who is studying the effect of a DNA-based vaccination protocol on tumour infiltrating 
leukocytes. The DNA-based vaccine is composed of a plasmid coding for α–enolase 
(ENO1), an enzyme strongly expressed by PDAC cells with high immunogenicity potential 
[124]. The plasmid is then electroporated into the femoral muscle of KC mice (i.e. mice 
bearing the tumorigenic KrasG12D mutation, only in pancreatic cells), in order to force the 
expression of ENO1 in a peripheral organ. Vaccination of tumour-bearing mice has been 
shown to have a protective effect in this preclinical model [124]. In particular, anti-ENO1 
vaccination promoted the antigen-specific immune response increasing. So far I have been 
able to analyse only a few mice and I have observed that TLT neo-genesis is significantly 
induced in vaccinated mice (pENO) compared to both control groups (empty vaccine 
(pEmpty) treatment and unvaccinated mice (Ctrl)) (Figure 3.10). This suggests that the 
antigen stimulation, mediated by the vaccination protocol, drives TLT formation by 
promoting both recruitment and spatial organization of lymphocytes in the 
microenvironment.  
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Figure 3.10. An immunotherapeutic DNA-vaccine induces neo-genesis of intratumour 
TLT in a preclinical model of PDAC. Induction of TLT by an antitumor vaccination in 
KrasG12D-Pdx1-Cre mice. Histological sections of murine PDAC from non-treated mice (NT; 
n=10) or mice vaccinated with empty vector (empty; n=4) or a vector encoding ENO1 
(ENO1; n=7) stained with hematoxylin-eosin (dotted line indicates an intratumour TLT) (A). 
Graph refers to the area occupied by TLT (B). P-value by Students’ t test; Horizontal Bars 
represent mean, vertical bars SEM; *: P<0.05; Scale bars: 500µm. 
 
 
The increase was paralleled by an increase in CD3-TILs, suggesting that induction of TLT 
by immunotherapeutic approaches could be strategic to increase recruitment of T cells 
(Figure 3.11).  
 
 
Figure 3.11. An immunotherapeutic DNA-vaccine induces increased recruitment of T 
cells in a preclinical model of PDAC. Histological sections of murine PDAC from non-
treated mice (NT; n=10) or mice vaccinated with empty vector (empty; n=4) or a vector 
encoding ENO1 (ENO1; n=7) stained with anti-CD3. IRA% of CD3-TILs (A) is significantly 
increased by vaccination compared to untreated mice (B). P-value by Students’ t test; bars 
represent SEM; **: P<0.001. Scale bars: 100µm. 
 
Importantly, vaccination generated a pool of long-lived T cells specific for ENO-1 and able 
to secrete IFN-γ after in vitro exposure to cognate antigen, only in ENO1-vaccinated mice 
compared to mice vaccinated with the empty vector (Figure 3.12). 
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Figure 3.12. ENO1 vaccination induces specific T cell response. Spleen cells from 
untreated or ENO1-vaccinated mice were stimulated on an enzyme-linked immunosorbent 
spot plate in the presence (black dots) or absence (white dots) of rENO1. Anti-ENO1 T cells 
are significantly induced in ENO1-vaccinated mice (ENO1 n=2), but not in untreated mice 
(NT; n=2). Numbers in the graph represent the mean number of specific spots (rENO1) 
normalized to the background (Medium). All conditions were performed in triplicate. Red 
lines represent mean, vertical bar SEM; P<0.05 (*) by Students’ t test; all conditions were in 
quadruplicate. 
 
 
3.8 Targeting tumour infiltrating B cells unleashes the antitumour immune 
response in murine PDAC 
 
To further investigate the contribution of scattered tumour infiltrating B cells (B-TILs) on 
PDAC, we needed to discriminate between B cells that are interspersed versus those that 
are organized in tertiary lymphoid tissue, either finding a strategy selectively targeting one 
of those, or alternatively, adopting a model in which only one of the two B populations is 
present. We reached the conclusion that targeting B cells with an anti-CD20 antibody in an 
orthotopic model could well fulfil our requirements. The anti CD20 antibody, in fact, has been 
shown to selectively target B-TILs and spare B cells within lymphoid tissues [111, 112]. I 
tested the effect of an anti-CD20 antibody targeting B cells (clone 5D2, Genentech) in an 
orthotopic implantable model of PDAC, treating the mice with the antibody 3 days post 
tumour injection. Differently from the genetic model previously mentioned, I did not observe 
formation of B-TLT in any of the tumour-bearing mice, likely due to the rapid tumour growth 
(21 days) and to the absence of a chronic inflammatory reaction. In contrast, scattered B 
cells still infiltrated the tumour tissue, confirming that B-TILs act independently from B-TLT 
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in this preclinical model. Circulating B cells were dramatically depleted by a single injection 
of the antibody (Figure 3.13, A), and the effect persisted until the end of the experiment 
(Figure 3.13, B), while the number of other circulating leukocytes (including CD3+ T cells 
and CD11b+ myeloid cells) was not significantly affected (Figure 3.14, A-B).  
 
 
 
 
 
 
 
Figure 3.13. Depletion of B cells by an anti-CD20 antibody in a murine implantable 
PDAC model. Mice were orthotopically injected with the PDAC cell line Panc02 and 
administered either an irrelevant antibody (IgG2A) or α-CD20 on day 3 post injection. (A) 
Exemplificative FACS plot showing depletion of circulating blood CD19+ B cells. (B) B cell 
depletion started at day 3 and lasted until the end of the experiment. Means relative to one 
of three independent experiments is shown (n=3 mice, IgG2A; n=4 mice α-CD20); bars 
represent SEM; P<0.05 (*), P<0.001 (**) and P=ns refer to Students’ t test. 
 
 
 
 
Figure 3.14. Blood cell counts after α-CD20 treatment. Mean counts of circulating CD3+ 
T cells (A) and CD11b+ myeloid cells (B) in IgG2A (n=3) and α-CD20 treated (n=3) mice, at 
different time points. Bars represent SEM; P<0.05 (*), P<0.001 (**) and P=ns refer to 
Students’ t test. 
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Consistent with the reduction of circulating B cells, also the number of B-TILs scattered in 
the tumour microenvironment was significantly reduced by the treatment (Figure 3.15, left 
panel). This confirmed that the depletion of circulating B cells is sufficient to prevent the 
accumulation of these cells in the tumour microenvironment, providing a valuable tool to 
dissect the role of B-TILs in this preclinical model of PDAC. The tumour volume was 
measured in a-CD20 treated and control tumour bearing mice (Figure 3.15, right panel). 
Despite a profound depletion of B-TILs, a-CD20 treatment alone was not sufficient to 
significantly reduce the tumour growth. This might suggest that B-TILs are only indirectly 
involved in controlling tumour growth, for instance by sustaining functions of other effector 
immune cells. 
 
 
 
 
 
 
Figure 3.15. Targeting tumour infiltrating B cells unleashes immune response in 
murine PDAC. (A) Exemplificative FACS plot showing depletion of tumour infiltrating CD19+ 
B cells. (B) Percentage of CD19+ B cells infiltrating PDAC tumours is reduced by α-CD20 
treatment. One of three experiments performed is shown (n=8 mice, IgG2A; n=9 mice α-
CD20; bars represent SEM; P=0.004 by Students’ t test). (C) Tumour growth was slightly 
but not significantly reduced by α-CD20 treatment. Mean of three independent experiments 
is shown: n=20 mice, IgG2A; n=16 mice α-CD20; bars represent SEM; P<0.05 (*), P<0.001 
(**) and P=ns refer to Students’ t test.   
 
I decided to dissect the contribution of B-TILs to the anti-tumour immune response in this 
orthotopic model of PDAC by comparing the immune signature of the leukocyte population 
isolated from PDAC tumours from control and B-TILs depleted (α-CD20-treated) mice. 
Depletion of B-TILs resulted in a significant increase in genes related to T cell and NK cell 
infiltration (CD4, CD8, NCR1), activation (GMZA, GMZB, IL12, IFNG, and TNFA) and 
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recruitment (CXCR3) (Figure 3.16). These results show that, in an implanted tumour model 
devoid of TLT, depletion of B-TILs increases the recruitment of important components of the 
antitumor immune response.  
 
 
 
 
Figure 3.16. Immune signature after α-CD20 treatment. RNA from leukocytes isolated 
from PDAC of mice treated with IgG2A or α-CD20 shows induction of genes related to T cell 
infiltration and activation. Mean of three independent experiments is shown: n=4 mice, 
IgG2A; n=4 mice α-CD20; bars represent SEM; P<0.05 (*), P<0.001 (**) refer to Students’ t 
test. 
 
To gain more insight on the biological relevance of the signature obtained, the set of genes 
was interrogated by a systems biology approach based on Ingenuity Pathway Analysis 
(IPA, http://www.ingenuity.com). Surprisingly, within the panel of genes analysed, depletion 
of B cells with α-CD20 induced a significant functional enrichment of genes involved in 
lymphoid tissue structure and development, CD8+ T cell infiltration and maintenance and 
differentiation of T cells (Figure 3.17). Together, those findings confirmed that upon B-TILs 
depletion mRNA levels of key T cell effector genes are significantly increased, suggesting 
that in this model B-TILs might impair effector functions of T cells. 
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Figure 3.17. Immune signature after α-CD20 treatment. Systems biology analysis 
showing the relationship between molecules and biological functions based on the genes 
modulated after depletion of B cells. The analysis highlights significant activation of 
biological functions related to lymphoid tissue structure and development, CD8+ T cell 
infiltration and maintenance and differentiation of T cells. 
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3.9 Discussion 
In this first section, I have addressed the occurrence of TLT in the tumour microenvironment 
of pancreatic cancer, its ability to promote anti-tumour immune responses and its relevance 
as a prognostic immune variable and in the design of novel immunotherapeutic strategies. 
Important point of novelty of this work relates to the distinct assessment of an immune 
population (B cells in this case) in the tumour microenvironment, according to its spatial 
distribution. We show that the prognostic behavior of B cells in PDAC is tightly linked to their 
topological organization within the microenvironment. This dual spatial organization may 
reflect a distinct function. The strategic localization of B cells in association with T cells within 
highly organized lymphoid tissue could reflect how B and T cells interact during the 
organization of a local immune response. B cells can modulate the immune response by 
mechanisms involving cytokine secretion and antigen presentation [28, 129]. Also, B cells 
within a lymphoid site associated to a follicular signature, suggesting that they could be 
involved in an ongoing follicular immune response with a protective antitumor role. Finally, 
CD20-TLT correlated with CD8+ T cell infiltration, suggesting that B cells within TLT could 
concomitantly be engaged in humoral and T cell responses. Overall, several 
immunotherapeutic approaches are under evaluation in human PDAC, including vaccination 
protocols directed against PDAC antigens, which would benefit from a microenvironment 
favourable for TLT induction.  
As to the CD20-TIL component, on the basis of our clinical and preclinical data we 
hypothesize that the egress of B cells into the tissue is detrimental to an effective anti-tumour 
response and might reflect a non-specific pro-tumour inflammatory reaction. In accordance, 
the depletion of tumour infiltrating B cells was sufficient to reinstate a genetic signature 
associated to an effective CD8+ antitumour immune response in a PDAC preclinical model 
without TLT. The role of B cells in the progression of solid tumours has fostered studies 
concerning their targeting by anti-CD20 antibodies [130-135]. Based on our data, the design 
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of anticancer strategies envisaging the depletion of B cells should take into account the 
possibility to selectively target CD20-TILs but not CD20-TLT.  
In addition to our findings, the depletion of B cells has been reported to produce contrasting 
effects according to tumour setting and depletion strategy. In mice genetically devoid of B 
cells both the spontaneous and the therapeutic vaccination-induced immune response 
against tumour were enhanced compared to wild-type mice [135-141]. On the contrary, in 
transplantable tumour models, the anti-CD20 mediated acute depletion of B cells showed 
variable effect according to tumour cell line used [142-144]. While the impact of B cell 
targeting over tumour growth is clearly established, the mechanisms involved in determining 
a positive or negative role of B cell targeting need further investigation. Interestingly, the 
kinetic of B cell depletion by anti-CD20 antibodies varies among different B cell sub-
populations (i.e. circulating, marginal zone, peritoneal) [131]. Thus, it is reasonable to 
suppose that contradictory effects of B cell depletion observed in preclinical models of tumor 
might reflect differential contribution of B cells subsets in coordinating the immune response. 
Moreover, in non–tumor conditions, anti-CD20 therapy has resulted ineffective in depleting 
CD20+ cells in tertiary lymphoid organs [130], suggesting that B cells might receive survival 
signals within lymphoid niches [131]. The differential sensitivity that B cells display to anti-
CD20 treatment according to their differentiation status and localization could be exploited 
to design tailored approaches, assuming that a rigorous evaluation of B cell spatial 
distribution is performed. 
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4. Effect of tumour 
metabolism on 
immune infiltrate 
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4.1 Background and goal 
 
 
Among the most important interactions occurring in the tumour microenvironment, the 
pathways that regulate immune cell function and metabolism are tightly linked [94, 145, 146]. 
Energy and biosynthetic precursors are essential for T cell immune function in homeostatic 
conditions [147]; as a result, metabolic dysfunction, which is often associated to pathologic 
states, impacts on the efficacy of the immune response. The condition of nutrient deprivation 
is commonly present in tumour settings, suggesting that metabolic microenvironmental cues 
could potentially impact on the fulfilment of an effective antitumor immune response [1]. 
Overall, metabolic reprogramming is considered a hallmark of cancer progression [1, 91] 
and its therapeutic modulation is emerging as a strategy to ameliorate the antitumour 
immune response [148]. 
PDAC cells escape immune recognition and devise an immunosuppressive 
microenvironment, by mechanisms including limited immunogenicity, inadequate immune 
cell infiltration and myeloid immune-regulatory networks [88, 149, 150]. However, 
surprisingly, the influence of metabolic cues on immune cell function has not been 
addressed.  
In an effort to characterize environmental factors affecting immune cell function, in this part 
of the project, I have investigated the relationship between the tumour metabolic profile and 
the immune response in human PDAC, with the following main objectives: 
 
• Dissecting the influence of tumour metabolism over infiltrating immune cell phenotype 
in human PDAC 
• Inhibit tumour glycolysis to evaluate potential therapeutic implications in preclinical 
models of PDAC 
• Combine Immunotherapy with tumour glycolysis inhibiting strategies 
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4.2 Metabolomics analysis of pancreatic juice indicates an alteration in glucose 
metabolism in pancreatic ductal adenocarcinoma patients 
 
Pancreatic juice is the liquid that collects the secretions of pancreatic duct and acinar cells. 
It contains pancreatic digestive enzymes and a high concentration of bicarbonate ions, 
essential to neutralize gastric acid, and to allow proper enzymatic activity. Pancreatic juice 
can be readily sampled from the main pancreatic duct both during pancreasectomy, and 
with other less invasive procedures (Figure 4.1, A) [151]. Cancer cells present metabolic 
alterations that could result in modification of biological fluids and, in the case of PDAC, such 
alterations could modify the composition of ductal cell secretions. In order to get a 
comprehensive overview of the altered metabolic profile of PDAC specimens, we compared 
the metabolite content of pancreatic juice obtained from patients with pancreatic 
adenocarcinoma to control patients with pancreatic pathologies histologically distinct from 
PDAC (including pancreatitis, neuroendocrine tumours, papillary tumours). We collected 
pancreatic juices from 40 patients who underwent pancreasectomy at our Institute (Figure 
4.1, B). The patient cohort (Cohort 2. Table 3) included 31 PDAC and 9 other non-PDAC 
pathologies (4 papillary-ampulla tumours, 2 pancreatitis, 2 neuroendocrine tumours, 1 
intraductal papillary mucinous neoplasm (IPMN)). We then obtained a broad metabolic 
picture of PDAC specimens by performing a metabolomics study using 1H nuclear magnetic 
resonance (NMR) spectroscopy. Due to the unexplored properties of pancreatic juice, we 
chose NMR, since compared to other metabolomics assays (e.g. liquid chromatography and 
mass spectrometry, LC-MS) it is less sensitive, though more accurate in identifying 
metabolites. In particular, we collected both one-dimensional (1d) Nuclear Overhauser 
Effect Spectroscopy (NOESY) and 1d Carr-Purcell-Meiboom-Gill (CPMG) spectra [152] on 
40 pancreatic juice samples. As depicted in Figure 4.1, C, we employed the CPMG spectra 
for multivariate statistical analysis (PDAC in blue, non-PDAC in green), which allow us to 
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appreciate the details of the smaller molecular weight metabolites by filtering the broad NMR 
signals of macromolecules (e.g. lipoproteins, lipids etc.). After spectral bucketing (0.02 ppm 
buckets width) by AMIX software (Bruker Biospin), a total spectral area normalization took 
place for all buckets in order to avoid any dilution differences between the samples. 
Subsequently, a supervised OPLS-DA (orthogonal projection latent structure discriminant) 
analysis segregated the two groups (Figure 4.1, D), with an accuracy of more than 80% 
obtained by cross-validation (Figure 4.1, E), indicating that pancreatic adenocarcinoma 
could be singled out from other pancreatic pathologies through metabolic profiling. The 
produced latent variables plots (LV) of the OPLS-DA analysis components and the 
estimated variable importance in the projection (VIP) score of each group (variables with 
VIP > 1.0 were initially considered significant for each model) were used for the detection of 
the weighted variables (NMR signals–buckets), responsible for the group classification. 
These signals corresponded to the metabolites reported in Figure 1D. The statistical 
significance (p) of each metabolite was calculated by univariate one-way ANOVA analysis, 
extra refined by an n-fold cross-validation implementation, by splitting the data into n sub-
datasets while performing the ANOVA test (e.g. cross-validated ANOVA) [153].  The fold 
change of the concentration of 18 metabolites (Figure 4.1, F), measured by their NMR 
signals deconvolution-integration, showed that only concentration of lactate, the end product 
of glycolysis, resulted increased in PDAC patients, suggesting a selective alteration of 
glucose metabolism in ductal carcinoma cells. 
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Figure 4.1. Metabolomic analysis of pancreatic juice. (A) Schematic representation 
depicting the secretion of pancreatic juice into the pancreatic duct and its collection during 
surgery. (B) Schematic description of the two cohorts of PDAC patients employed in the 
study. (C) 1H NMR CPMG spectra of PDAC samples (in blue) and non-PDAC samples (in 
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green) providing details on the small molecular weight metabolites contained in the 
pancreatic juices. (D) Supervised multivariate OPLS-DA analysis on CPMG spectra from 
PDAC samples (green squares) and non-PDAC samples (red diamonds) segregated the 
two groups (each one outlined by a spider plot), with an accuracy of 76% obtained by cross-
validation. (E) ROC curves for the cross-validation of OPLS-DA analysis of PDAC (left) and 
non-PDAC (right). (F) “n Fold” concentration change calculated using the mean value of 
each metabolite in each group (PDAC vs non-PDAC). The integrals of metabolite signals 
have been normalized with total area of the spectra. The green bars indicate a p value < 
0.05, and the red ones p > 0.05. Only lactate and glucose show a higher increased 
concentration trend in PDAC samples. 
 
 
4.3 Glucose metabolism correlates with density of PD-1+ cells in human and 
murine PDAC 
We next considered whether the peculiar glucose metabolism observed in PDAC specimens 
correlated with specific immune profiles. Accelerated glucose metabolism in tumour cells 
(the so-called “Warburg effect”) relies on modulation of key glycolytic enzymes, including 
the glucose transporter 1 (GLUT-1)	 [152]. To obtain a reliable indication of the Warburg 
effect in human PDAC tissues, I have analysed the expression of GLUT-1 in 18 PDAC 
specimens (Figure 4.1, B) by immunohistochemistry. Immunohistochemical staining 
evidenced a high degree of heterogeneity of GLUT-1 expression among pancreatic ducts, 
ranging from low (Figure 4.2, A) to very high positivity (Figure 4.2, B). Notably, GLUT-1 
expression was higher in high-grade tumours (Figure 4.2, C), suggesting an association 
between a more aggressive phenotype and a higher glycolytic activity of pancreatic tumour 
cells. Then, to analyse how the tumour metabolic status correlates with the immune 
contexture in human PDAC, I have investigated potential associations of GLUT-1 
expression with the presence of tumour-infiltrating leukocyte populations. By 
immunohistochemistry, the density (immunoreactive area (IRA%)) of GLUT-1 and of 
immune cells, including PD-1+ cells (PD1-TILs, although it is impossible to unambiguously 
show that every PD1+ cell is a lymphocyte by imunohistochemistry), CD8+ tumour-infiltrating 
lymphocytes (CD8-TILs), CD20+ B lymphocytes (CD20-TILs), and CD68+ tumour-
associated macrophages (CD68-TAMs), were quantified (Figure 4.3, A-D). Intriguingly, the 
density of PD-1-TILs in 18 PDAC specimens correlated with the expression of GLUT-1 by 
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PDAC tumour cells (r=0.52, P=0.023) and notably, PD1-TILs were the only immune cells 
that showed a significant correlation with the expression of GLUT-1 (Figure 4.3, E-H). 
Moreover I have confirmed this immune-metabolic link in the Pdx1-Cre;KrasLSLG12D genetic 
preclinical model of PDAC. While very low or absent expression of GLUT-1 was detected in 
the pancreas of wild-type (WT) mice (Figure 4.4, A left), weak to very intense 
immunoreactivity was present in the pancreatic tumours of Pdx1-Cre;KrasLSLG12D mice 
(Figure 4.4, A right). An analogous expression pattern was shown by PD1-TILs (Figure 
4.4, B) and, consistent with human PDAC, a positive correlation between GLUT-1 
expression and PD1-TIL density was present (r=0.79, P=0.0007) (Figure 4.4, C). 
 
 
 
Figure 4.2. Immunohistochemical evaluation of GLUT-1 on PDAC paraffin sections. 
(A-B) Two representative specimens with low (A) and high (B) marker expression are 
shown. (C) Distribution of GLUT-1 expression (IRA%) according to tumour grade in 18 
PDAC patients. Scale bars: 500µm. Black lines in the graph represent median. 
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Figure 4.3. Immune variables in human PDAC specimens and their correlation with 
GLUT-1 expression. (A-D) Representative histological sections of human PDAC, stained 
for PD1-TILs (A), CD8-TILs (B), CD20-TILs (C) and CD68-TAMs (D). (E-H) Correlation of 
CD8-TILs (E), CD20-TILs (F), CD68-TAMs (G) and PD1-TILs (H) IRA% with GLUT-1 IRA%. 
P-value by Spearman’s simple linear regression analysis (E-H). Bars: 500µm (E-H) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. Correlation of Glut-1 and PD-1 expression in Kras-driven preclinical model 
of PDAC. Histological sections of pancreata of wild-type mice (left) and Pdx1-Cre;KrasG12D 
mice (right), stained with an anti-GLUT-1 (A) or anti-PD-1 (B) antibody. (C) Quantitative 
evaluation of the immunoreactive area (IRA%) reveals a linear correlation between the 
density of GLUT-1 and PD-1 in murine PDAC specimens (r=0.79, p=0.0007, n=23). P-value 
by Spearman’s simple linear regression analysis in (C). Bars: 500µm (A and B). 
 
 
4.4 Glucose uptake correlates with PD-1+ cells in preclinical models of PDAC 
To further investigate the association between the tumour metabolic state and PD1-TIL 
infiltration and to characterize the PD-1+ cells in the tumour microenvironment, I have 
analysed implanted tumours obtained from two different pancreatic cell lines displaying 
different glucose uptake. DT6606 and Panc-02 are cell lines derived respectively from early 
and late stage murine PDAC (see methods “PDAC preclinical models”) and were chosen on 
the basis of their glucose uptake, measured by in vitro accumulation of a fluorescent 
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analogue of glucose (2NBDG) (Figure 4.5, A). Cells were incubated with 2NBDG, and 
representative images were collected by inverted fluorescence microscope to measure 
2NBDG fluorescent signal (Figure 4.5, B). This analysis revealed that Panc02 cell line 
showed a significantly higher accumulation of 2NBDG compared to DT6606. On this 
premise I have subcutaneously injected DT6606 and Panc02 cell lines in mice, in order to 
test if the differential glucose accumulation rate was maintained after in vivo growth, and to 
characterize the phenotype of tumour infiltrating T cells in DT6606 and Panc02 derived 
tumours (Figure 4.5, C). Tumours obtained from the two tumour cell lines were not 
significantly different in size (Figure 4.5, D). The increased capability of accumulating 
glucose of Panc02 cells was retained after 3 weeks of growth in vivo, as measured by ex 
vivo imaging after injection of the fluorescent probe deoxy-D-glucose (2-DG-750). Analysis 
of 2-DG-750 fluorescence was performed on the excised tumour mass (Figure 4.5, E), to 
avoid confounding signals from surrounding tissues and revealed that Panc02 tumours up 
took significantly more glucose than DT6606 tumours (Figure 4.5, F). Consistent with the 
correlation between GLUT-1 expression and PD-1+ T cell infiltrate observed in both human 
and murine PDAC (Figure 4.3 and 4.4), Panc02 tumours contained a higher percentage of 
PD1+ cells within CD8+ lymphocytes compared to DT6606 tumours (Figure 4.6, A and B), 
moreover CD8+/PD1+ T cells showed a significant increase in PD1-MFI (Mean Fluorescence 
Intensity) meaning that both the frequency of PD1+ cells (Figure 4.6, B) and the expression 
of this receptor (Figure 4.6, C) were increased in Panc02 tumours. Remarkably, this 
difference was not a general feature of immune infiltrating cells, since the percentage of 
CD3+ and CD8+ cells was similar in DT6606 and Panc02 tumours (Figure 4.6, D), 
highlighting a selective increase of PD1 expression in highly metabolic tumours. Moreover 
the accumulation of CD8+/PD1+ cells was a specific feature of tumour infiltrating cells. In fact 
I measured the expression of PD1 on T cells from the inguinal lymph nodes of naïve and 
tumour-bearing mice (draining lymph node) and I compared them to tumour infiltrating T 
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cells (TILs). While there was only a slight increase in CD8+/PD1+ cells in the tumour draining 
lymph nodes compared to lymph nodes from naïve mice, their percentage was markedly 
inferior to the percentage of CD8+/PD1+ TILs (Figure 4.6, E-F). This highlighted that PD1 
upregulation on T cells is driven by environmental cues specifically found in the tumour 
tissue. 
 
 
 
Figure 4.5. Glucose uptake characterization in implantable preclinical model of PDAC. 
In vitro fluorescence imaging of DT6606 and Panc02 exposed to 2NBDG, representative 
pics are reported (A). 2NBDG uptake by DT6606 and Panc02, Mean Fluorescent Intensity 
(MFI) is represented in the dot plot. Number of cells per replicate was at least 20 per group, 
mean values of three replicates are represented (B). Schematic representation of the PDAC 
preclinical model. DT6606 and Panc02 cell line are injected subcutaneously, and mice are 
sacrificed after 21 days from tumour cell injection. Tumour cells’ glucose uptake measured 
after administration of the glucose fluorescent analogue 2DG-750 (Perkin Elmer) (C). 
Comparison of DT6606 (n=8) and Panc02 (n=7) tumour volume at sacrifice; one 
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representative experiment is shown (D). Representative tumours imaged ex vivo after i.v. 
injection of 2DG-750 (E). Measure of the Average Radiant Efficiency relative to 2DG-750 
fluorescent signal in DT6606 (n=11) and Panc02 (n=12) tumours; graphs refer two 
independent experiments (F). Scale bars: 100µm (A); P-values are calculated by Mann-
Whitney U-test (ns>0,05, **<0,01, ****<0,0001); black lines indicate mean, vertical bars 
represent SEM (B, D and F). 
 
 
Figure 4.6. Expression of PD-1 on tumour infiltrating T cells in PDAC preclinical 
model. FACS dot plot showing PD-1 expression on CD8+ TILs, from DT6606 and Panc02 
tumours (A). Statistical analysis of PD-1 expression as percentage of CD8+ T cells or as 
mean fluorescence intensity (B and C respectively). Frequency of CD3+ or CD8+ T cells as 
percentage of CD45+ TILs in DT6606 and Panc02 tumours (D). FACS dot plot of lymph 
nodal CD8+ T cells from inguinal lymph nodes of naïve (left) or tumour-bearing mice (right) 
(E). Statistical analysis of CD8+/PD1+ T cells distribution in inguinal lymph nodes, of naïve 
or tumour bearing mice, or in tumours (F). Graphs refer to at least two independent 
experiments (DT6606 n=9; Panc02 n=11; Naïve lymphnode n=3); P-values are calculated 
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by Mann-Whitney U-test (ns>0,05, *<0,05, **<0,01, ****<0,0001); black lines indicate mean, 
vertical bars represent SEM (B, C, D and F). 
 
 
4.5 Targeting of glycolysis impacts on the accumulation of PD1-TILs in PDAC 
tumours 
To analyse whether the increased metabolism of Panc02 cells was sufficient to determine 
PD1-TIL accumulation, two different approaches were adopted in order to inhibit glycolysis 
in Panc02 cells (Figure 4.7, A and 4.8, B). Pharmacological inhibition of the Warburg effect 
was achieved by administering the glycolysis inhibitor 2-deoxy-glucose (2-DG) in drinking 
water, for 2 weeks (Figure 4.7, A). At sacrifice neither tumour volume nor the percentage of 
CD3+ and CD8+ lymphocytes (Figure 4.7, B and C respectively) was significantly affected 
by the 2DG treatment. In contrast, inhibition of the glycolytic pathway by 2-DG, was sufficient 
to significantly reduce PD1-TIL infiltration in Panc02 tumours (Figure 4.7 D-E). Moreover, 
PD-1 MFI relative to CD8+ lymphocytes was significantly reduced after 2DG treatment 
(Figure 4.7 F), confirming a direct involvement of glucose metabolism in the regulation of 
PD-1 expression. Despite its use in clinical trials, the administration of a non-specific 
glycolysis inhibitor such as 2-DG, could also interfere with glucose metabolism in effector T 
cells, affecting both their life span and effector functions [123]. Thus, we evaluated genetic 
silencing of glycolysis in Panc02 cells, in order to blunt the glycolytic metabolism only of 
tumour and not of immune cells. Glycolytic enzymes and other markers related to metabolic 
consumption are reliable indicators of the metabolic state of tumour cells. In a preliminary 
analysis, I have assessed the expression of main glucose transporters, and rate-limiting 
glycolytic enzymes in Panc02 cells (Figure 4.8, A) and opted for phosphofructokinase-m 
(PFK-m). This enzyme synthetizes fructose-1,6-bisphosphate, the first intermediate of 
glucose exclusively involved in the glycolytic reaction. This could reduce potential alterations 
of other metabolic pathways interconnected with glycolysis, such as the pentose phosphate 
pathway involved in nucleotide biosynthesis. Panc02 cells stably knocked-down with a 
shRNA targeting PFK-m (shPFK) and the corresponding control cell line stably expressing 
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a scramble sequence (shSCR), were generated. After 10 days of puromycin selection, the 
Pfk-m transcript was measured in both sh-SCR and sh-PFK cell lines and the gene silencing 
in sh-PFK was 75% compared to sh-SCR tumours (2-DDCt=0,25 arbitrary units) (Figure 4.8, 
B). The two cell lines were implanted in mice, to originate tumours with opposite glycolytic 
rates and tumour growth was monitored for 24 days post-injection (Figure 4.8, C). This was 
not sufficient to affect tumour growth, nor the percentage of tumour infiltrating CD3+ and 
CD8+ lymphocytes (Figure 4.8, D and E respectively). Notably, genetic targeting of glucose 
metabolism significantly reduced the frequency of PD1-TILs within CD8+ cells infiltrating 
Panc02 tumours (Figure 4.8, F), ultimately confirming the link between glucose metabolism 
and CD8+/PD1+ T cell infiltration. This result also suggests that targeting of tumour 
metabolism could be evaluated as a strategy to impact on the type of immune infiltration.  
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Figure 4.7 Pharmacological inhibition of glycolysis down-regulates PD-1 expression 
in tumour infiltrating CD8+ T cells. Schematic representation of the experiment: seven 
days post subcutaneous injection of Panc02 cells, mice were treated with 0,5% 2-DG in 
drinking water or left untreated (A). Statistical analysis of tumour volume collected at 
sacrifice (CTRL n=15; 2DG n=14); two independent experiments are shown (B). 
Comparison of CD3+ and CD8+ TILs as percentage of CD45+ cells between control (n=5) 
and treated (n=4) group; one representative experiment is shown (C). FACS dot plot of 
representative samples showing PD-1 expression on CD8+ TILs in control and 2-DG treated 
mice (D) and relative statistical analysis of PD-1+ cells percentage and PD-1  MFI (E and F 
respectively), both relative to CD8+ TILs; two independent experiments are shown (CTRL 
n=12; 2DG n=12). P-values are calculated by Mann-Whitney U-test (ns>0,05, *<0,05); black 
lines indicate mean, vertical bars represent SEM (B, C, E and F). 
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Figure 4.8 Genetic silencing of key glycolytic enzyme down-regulate PD-1 expression 
in tumour infiltrating CD8+ T cells. Preliminary analysis of genes encoding key glycolytic 
enzymes in Panc02 cell line (A). Semi quantitative RT-PCR to calculate gene silencing in 
sh-PFK cell line after two weeks of puromycin selection. The experiment was performed in 
triplicate, and graph shows fold change of Pfk-m transcript calculated as 2-DDCt, where DDCt 
refers to mean DCt found in sh-SCR cell line (B). Schematic representation of the 
experiment: sh-SCR (high glycolysis) and sh-PFK (low glycolysis) cell lines were 
subcutaneously injected and tumour growth was allowed for 21 days post-injection (C). 
Tumour growth curve showing that sh-PFK tumours have the same progression of sh-SCR 
tumours in vivo (D). FACS analysis showing CD3+ and CD8+ T cells as percentage of CD45+ 
alive cells, and PD1+ T cells as percentage of CD8+ T cells in both sh-SCR and sh-PFK 
tumours (E and F respectively). D and E: n=14 (shSCR) and n=13 (shPFK), F: n=11 
(shSCR) and n=11 (shPFK), two independent experiments are shown. P-values are 
calculated by Mann-Whitney U-test (ns>0,05, *<0,05); black lines indicate mean, vertical 
bars represent SEM (B, E and F). 
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4.6 Combinatorial targeting of glucose metabolism and PD-1/PD-L1 axis in vivo 
To test whether modulation of the Warburg effect in Panc02 PFK-silenced cells was 
sufficient to determine a different responsiveness to anti-PD1 treatment, we administered 
the antibody twice a week until sacrifice to mice implanted with Panc02 shSCR or Panc02 
shPFK (Figure 4.9, A). Tumour growth in tumours obtained from both shSCR and shPFK 
cells treated with anti-PD1 antibody was slower compared to mice treated with isotype 
control antibody, but the reduction in tumour growth after treatment was statistically 
significant only in shPFK tumours (Figure 4.9, B). This corresponded to a reduction in 
tumour mass at sacrifice (Figure 4.9, C). To further investigate metabolic reprogramming 
occurring in cancer cells after both Pfk-m silencing and anti-PD1 treatment, I isolated CD45+ 
tumour infiltrating leukocytes (CD45+ cells) from tumour and stromal CD45- cells at sacrifice, 
and evaluated the expression of genes encoding for glycolytic enzymes in CD45- cells. All 
genes that showed a significant modulation (p<0,05) between sh-PFK, treated or not with 
the anti-PD1 immunotherapy, and control groups were included in the heatmap (Figure 4.9, 
D). Surprisingly, I observed that in sh-PFK tumours, genes involved in glycolytic reactions 
up-stream to Pfk-m, including Glut-1 (glucose transporter 1), HK-2 (Hexokinase-2), and Pfk-
FB3 (phosphofructokinase-fructose bisphosphatase 3) were selectively down-regulated 
compared to both treated and untreated shSCR tumours. On the contrary, genes 
responsible of glycolytic reactions downstream of Pfk-m, Eno1 (enolase 1), PK-M1/2 
(pyruvate kinase), Pdk2 (pyruvate dehydrogenase kinase 2) and Mct4 (monocarboxylate 
transporter 4), resulted significantly up-regulated in sh-PFK tumours. The up-regulation of 
glycolytic enzyme transcripts is frequently observed upon substrate restriction. This finding 
is in line with the assumption that Pfk-m knockdown caused a restriction in the availability of 
downstream glycolytic metabolites, thus confirming that glucose metabolism of sh-PFK 
tumours has been targeted and its alteration is maintained both after in vivo growth and after 
anti-PD1 immunotherapy. In order to explain the differential responsiveness to anti-PD1 
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treatment in our setting, the expression of the PD1 ligand (PD-L1) was measured, by semi 
quantitative RT-PCR, in all the cell lines used in our models. Surprisingly, the highest 
glycolytic cell line (Panc02-shSCR) showed the most abundant expression of PD-L1 mRNA 
compared to the lowest glycolytic cell line (DT6606), and accordingly, Pfk-m knock-down 
cells (Panc02-shPFK), with a reduced glycolytic activity, displayed an intermediate 
expression. This finding suggests a possible interconnection between glycolysis and the 
expression of the immune regulatory molecule PD-L1 (Figure 4.9, E).  
Next we evaluated a panel of immune-related genes in CD45+ cells, isolated from sh-PFK 
tumours treated with anti-PD1 antagonist and from their relative sh-SCR control tumours, 
by performing a gene expression array (RT2 Profiler PCR Array, QIAGEN). Among the 84 
genes analysed, those that presented a low modulation (p>0,05) comparing shPFK and 
shSCR CD45+ cells, were excluded from the analysis. Significantly modulated genes (n=41) 
are reported in the heatmap (Figure 4.9, F), which has been calculated by hierarchical 
clustering of normalized gene expression (z-score). CD45+ cells from shPFK and shSCR 
tumours segregated in two different clusters depending on their gene expression profile, 
suggesting that the modulation of immune-related genes mediated by the anti-PD1 
immunotherapy is influenced by the metabolic state of tumour cells. In particular, the gene 
expression array revealed that comparing CD45+ cells from shPFK and shSCR tumours, the 
anti-PD1 treatment up-regulated genes involved in antigen presentation (HK2-K1 and H2-
D1), T and NK cell recruitment (CXCL9, CCL4, CXCR4, CCR5), inflammatory transcription 
factors (NF-kB and STAT1) and cytokines (Tnf, IL12b, IL1a, IL1b); concomitantly, CD45+ 
cells from shPFK displayed a significant down-regulation of genes related to Th2/17 
polarizing cytokines (IL5, IL13, IL17a) and T cell immunosuppression (Ido1). The gene 
expression analysis reveals that the metabolic background of tumour cells significantly 
impacts on the expression of immune-related genes by CD45+-TILs upon anti-PD1 
treatment. This supports the hypothesis that metabolic cues in the tumour microenviroment 
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need to be considered in order to maximize the anti-tumour immune response, beside the 
targeting of specific immunological pathways. 
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Figure 4.9 Interaction between tumour glycolysis and anti-PD1 immunotherapy. 
Schematic representation of the experiment: mice were subcutaneously injected with sh-
SCR and sh-PFK tumour cell lines; 7 days post-injection mice were treated with 5 i.p. 
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injections of anti-PD1 or control isotype antibody, twice per week; 24 days post-injection 
mice were sacrificed and tumours collected (A). Tumour growth curve and tumour weight at 
sacrifice show the impact of anti-PD1 therapy on tumour progression in sh-SCR or sh-PFK 
tumours (B and C respectively). Heat map representing z-scores of significantly modulated 
genes in CD45- cells from sh-SCR and sh-PFK tumours treated with anti-PD1 or control 
isotype antibody (D). RT-PCR to evaluate the association between glycolysis and Pdl1 
mRNA expression, reported as arbitrary units (2-DCt) (E). Hierarchical clustering of 
significantly modulated genes in three samples of CD45+ cells from sh-SCR and sh-PFK 
tumours treated with anti-PD1 immunotherapy (F). (B and C) Graphs show means of at least 
two independent experiments; in the isotype-treated group n=9 in both shSCR and shPFK 
tumours, while in the anti-PD1 group n=15 in shSCR and n=14 in shPFK tumours; two-way 
ANOVA test was used and P values calculated by Tukey’s multiple comparisons post-test 
(ns>0,05, *<0,05). (E) Graph shows means of two independent experiments and P-values 
are calculated by Mann-Whitney U-test (ns>0,05; *<0,05; **<0,01); dots (B), black lines (C), 
or bars (E) indicate mean, vertical bars represent SEM. 
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4.7 Discussion 
 
 
The condition of nutrient deprivation frequently characterizes the tumour microenvironment. 
For this reason, a clear definition of tumour metabolic pathways can result in a better 
understanding of immune dysfunction in tumours. 
We approached this issue by a metabolomics analysis in pancreatic juice, which allows us 
to appreciate the variety of molecules downstream relevant biological pathways. In 
pancreatic cancer, well-known for its metabolic alterations, metabolomics analyses of serum 
[154], urine [155] and even salivary fluids [156] have been performed and have led to 
relevant information, including discrimination of benign from malignant pancreatic diseases. 
However, pancreatic juice has been less explored for this purpose. Here pancreatic juice 
was collected intra-operatively. However, in a perspective of identifying early informative 
clinical markers, the collection of pancreatic juice could also be achieved by endoscopic 
ultrasound, retrograde cholangio-pancreatography or by endoscopic collection of duodenal 
juice secretion. 
Multivariate statistical analysis of the NMR spectral data indicated significant group 
discrimination based on a disease-specific metabolic signature that singled out PDAC from 
other benign (pancreatitis) or less aggressive (papillary, neuroendocrine, IPMN) pancreatic 
pathological conditions. In particular, among 18 metabolites identified in pancreatic juice, 
only lactate exhibited a higher concentration in samples from PDAC patients, hinting to a 
specific alteration of glucose metabolism. A number of other metabolites were decreased in 
juices from PDAC patients, possibly suggesting the metabolic rewiring in favor of glycolysis. 
This comprehensive analysis, does not allow to investigate in detail the biochemical 
pathways ongoing in tumor cells, as it is the result of all the different cell types that contribute 
to the tumor metabolism, including stromal and immune cells. Nevertheless, the increased 
expression of the glucose transporter GLUT-1 in PDAC paraffin-embedded specimens 
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reflects an increased glucose uptake and further confirms a dis-regulated glucose 
metabolism, which, importantly, can be detected in situ, in pancreatic juice.  
 
A better knowledge of the metabolic reprogramming characterizing tumors and how it 
impairs the function of immune cells could have an important impact on the design of 
immunotherapeutic strategies [148]. We have attempted to shed light on the immune-
metabolic network by studying, in human PDAC specimens and in vivo preclinical models, 
how distinct tumor metabolisms correlate with the type of immune infiltration. Our data 
suggest that glucose metabolism is an important factor in the microenvironment of PDAC, 
by affecting the accumulation of PD1+ cells in tumors. This result entails important clinical 
consequences. First, histo-pathological evaluation of the immune infiltrate, which is the 
dominant approach to grade the relevance of immune variables in cancer, only applies to 
surgical specimens, while a less invasive, pre-surgical identification of markers correlating 
with immune variables could represent a considerable advancement. Expression of PD-1 
ligands in the tumor microenvironment has been validated as predictive biomarker of 
response to checkpoint inhibitors, with conflicting results [64]. Other mechanism-driven 
biomarker inquiries have shown that preexisting T-cell antitumor immunity is a prerequisite 
for increased susceptibility to immunomodulatory antibodies [157, 158]. Nonetheless, the 
mechanisms of resistance and variable response to checkpoint inhibitors remain poorly 
understood and suggest that factors other than the immunologic ones could emerge as 
important dictators of response to PD-1 targeted therapies. 
 
On this line, attention has been turned to metabolic variables. In melanoma patients, 
baseline concentration of lactate dehydrogenase (LDH) measured in blood routine tests has 
been identified as a predictive biomarker of response to anti CTLA-4 treatment [93, 159, 
160]. However, this marker is still not routinely used to influence therapeutic decisions, 
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possibly due to its rapid increase during stress responses. In [93] the authors suggested 
that LDH increase could mark the glycolytic switch of tumour cell metabolism, supporting 
the idea that the stimulatory effect of immunotherapy is dampened by the aberrant glucose 
metabolism in tumour microenvironment. Accordingly, we observed that targeting glycolysis 
significantly impacted the antitumor immune response mediated by anti-PD1 therapy. 
Although this synergism is reflected by the selective modulation of genes involved in 
antigen-specific immunity, the effect observed in vivo was only mild albeit significant. Being 
already measured in daily routine laboratory setting, the evaluation of LDH level could be 
easily translated to daily clinical practice. Interestingly, no mechanistic explanation for the 
predictive function of LDH levels to checkpoint inhibitors had been provided so far.   
In the case of pancreatic adenocarcinoma, however, these issues are still out of reach. In 
fact, the nature of the intense stroma preventing recruitment of immune cells has 
represented an obstacle to the introduction of strategies targeting the immune system.  
 
In this work, inhibition of glycolysis in tumor cells specifically affected PD1 expression in T 
cells, without impairing CD8+ T cell recruitment, suggesting that the metabolic profile of 
tumor cells can modulate the immune response by shaping the phenotype of cytotoxic T 
cells. It is known in literature that unavailability of metabolic substrates for the glycolytic 
reaction can lead to immune dis-regulation and inappropriate immune responses. 
Essentially, distinct metabolic pathways characterize T cells according to their functional 
state in the course of immune responses. In the case of cytotoxic T cells, a remarkable 
feature is the considerable and sudden increase in glucose uptake following the immune 
stimulus and differentiation to cytolytic effectors [146, 147], a process required to switch 
from the oxidative phosphorylation pathway to the glycolytic one, necessary to sustain rapid 
cell growth. However, formal demonstration that nutrient deprivation modulates PD1+ T cell 
frequency has not been provided yet. Alternatively to this “nutrient competition” scenario, 
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lactate and other metabolites are not only by-products of high-proliferating cells, but act as 
signaling molecules capable of negatively modulating immune cell functions [161-163]. Cell 
metabolism could have a role also in T cell exhaustion, a condition of unresponsiveness 
associated to chronic antigen stimulation, frequently observed during chronic infection and 
cancer [164, 165]. The PD-1-PD-L1 pathway, a prominent target in cancer immunotherapy, 
also induces metabolic reprogramming of T cell metabolism [166]. 
 
We also show an increased response to the anti-PD1 treatment in tumors metabolically re-
educated by glycolysis inhibition, indicating that manipulation of tumor metabolism could 
also result in the reboot of T cell function. This also suggests that combinatorial strategies 
concomitantly targeting metabolism and checkpoint inhibitors could be evaluated in a 
therapeutic perspective. However, we have not formally proved that PD-1 positive cells are 
exhausted. Despite their common association to T-cell inhibition and immunosuppressive 
conditions, PD1 expressing tumor-infiltrating cells have been also shown to be a favorable 
prognostic marker in HPV+ head and neck cancer [167]. Moreover, in chronic infections, 
PD1 cells are the ones producing cytokines [168]. This controversial function of the PD1 
molecule does not however contrast with the use of anti-checkpoint antibodies, which are 
supposed to act by blocking inhibitory signals engaging the PD1. Dysregulation in metabolic 
pathways could contribute to such inhibitory signals and, together with the possibility to 
synergize with other checkpoint inhibitors, need further investigation. 
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5. Concluding remarks  
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In this thesis I have summarized the main findings collected during my PhD training, which 
has been focused on relatively unexplored aspects of the immune infiltrate of pancreatic 
cancer. Pancreatic cancer is frequently reported as hypo-responsive to immunotherapeutic 
treatments, which have been little introduced for this tumour type, with a few exceptions (i.e. 
anti-CD40 and vaccination). During these years, I have nurtured the idea that the general 
view of pancreatic adenocarcinoma as a tumor environment hostile to immune infiltration 
could have hampered the introduction of immune-based approaches for this neoplastic 
disease. Based on my analyses and on the knowledge that I’ve acquired on the immune 
microenvironment of PDAC, a considerable number and types of immune cells populate 
pancreatic cancer tissues, suggesting that there is chance that targeting immune cells could 
result beneficial also for pancreatic cancer patients.  
In the first part, I have introduced a relatively new component of the immune contexture of 
different tumours, namely tertiary lymphoid tissue. The occurrence of TLT in the tumour 
microenvironment has two important outcomes on the design of immunotherapeutic 
approaches. To begin with, the presence of a lymphoid site could favour recruitment of 
immune cells and their in situ activation, thus it could increase responsiveness to adoptive 
cell therapies. Moreover, my analysis focused on the B cell component and suggesting their 
dual function in tumours reinforces the hypothesis that B cell targeting could be effective 
also in solid tumours. Finally, immunotherapeutic vaccination protocols could boost the 
function of TLT, as I showed here and as it has been already shown in literature [42], thus 
it could benefit from a microenvironment conducive to TLT formation. 
In the second part, my analysis of the intersection between tumour metabolism and PD-1+ 
cell infiltration suggests how a better knowledge of the metabolic reprogramming 
characterizing tumours and how it impairs the function of immune cells could have an 
important impact on the design of immunotherapeutic strategies. So far, the PD1-PDL1 axis 
has emerged as one of the most promising immunotherapeutic pathways already translated 
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into clinical practice. Surprisingly, however, the simple evaluation of the expression of such 
biomarkers has been reported as inaccurate in predicting therapy effectiveness [64]. Our 
data suggest that other factors, including metabolic variables could affect PD1 expression 
in T cells. We observed a significant tumour reduction upon anti-PD1 treatment only in 
tumours metabolically re-educated by glycolysis targeting. This indicates that manipulation 
of tumour metabolism could also result in the reboot of T cell function. This also suggests 
that combinatorial strategies concomitantly targeting metabolism and checkpoint inhibitors 
could be evaluated in a therapeutic perspective.  
  
	 95	
Bibliography  
 1.	 Hanahan,	D.	 and	R.A.	Weinberg,	Hallmarks	 of	 cancer:	 the	 next	 generation.	 Cell,	 2011.	
144(5):	p.	646-74.	2.	 Mantovani,	A.,	et	al.,	Cancer-related	inflammation.	Nature,	2008.	454(7203):	p.	436-44.	3.	 Schreiber,	R.D.,	L.J.	Old,	and	M.J.	Smyth,	Cancer	immunoediting:	integrating	immunity's	
roles	in	cancer	suppression	and	promotion.	Science,	2011.	331(6024):	p.	1565-70.	4.	 Vesely,	M.D.,	et	al.,	Natural	innate	and	adaptive	immunity	to	cancer.	Annu	Rev	Immunol,	2011.	29:	p.	235-71.	5.	 Gentles,	A.J.,	et	al.,	The	prognostic	landscape	of	genes	and	infiltrating	immune	cells	across	
human	cancers.	Nat	Med,	2015.	21(8):	p.	938-945.	6.	 Mantovani,	 A.	 and	 P.	 Allavena,	 The	 interaction	 of	 anticancer	 therapies	 with	 tumor-
associated	macrophages.	J	Exp	Med,	2015.	212(4):	p.	435-45.	7.	 Shalapour,	S.	and	M.	Karin,	Immunity,	inflammation,	and	cancer:	an	eternal	fight	between	
good	and	evil.	J	Clin	Invest,	2015.	125(9):	p.	3347-55.	8.	 Shankaran,	V.,	et	al.,	IFNgamma	and	lymphocytes	prevent	primary	tumour	development	
and	shape	tumour	immunogenicity.	Nature,	2001.	410(6832):	p.	1107-11.	9.	 Mlecnik,	B.,	et	al.,	Tumor	immunosurveillance	in	human	cancers.	Cancer	Metastasis	Rev,	2011.	30(1):	p.	5-12.	10.	 Gajewski,	T.F.,	H.	Schreiber,	and	Y.X.	Fu,	Innate	and	adaptive	immune	cells	in	the	tumor	
microenvironment.	Nat	Immunol,	2013.	14(10):	p.	1014-22.	11.	 Smyth,	M.J.,	et	al.,	Perforin-mediated	cytotoxicity	is	critical	for	surveillance	of	spontaneous	
lymphoma.	J	Exp	Med,	2000.	192(5):	p.	755-60.	12.	 Street,	 S.E.,	 et	 al.,	 Suppression	 of	 lymphoma	 and	 epithelial	 malignancies	 effected	 by	
interferon	gamma.	J	Exp	Med,	2002.	196(1):	p.	129-34.	13.	 Davidson,	W.F.,	T.	Giese,	and	T.N.	Fredrickson,	Spontaneous	development	of	plasmacytoid	
tumors	in	mice	with	defective	Fas-Fas	ligand	interactions.	J	Exp	Med,	1998.	187(11):	p.	1825-38.	14.	 Boshoff,	C.	and	R.	Weiss,	AIDS-related	malignancies.	Nat	Rev	Cancer,	2002.	2(5):	p.	373-82.	15.	 Frisch,	M.,	et	al.,	Association	of	cancer	with	AIDS-related	 immunosuppression	 in	adults.	JAMA,	2001.	285(13):	p.	1736-45.	16.	 Kirk,	 G.D.,	 et	 al.,	 HIV	 infection	 is	 associated	 with	 an	 increased	 risk	 for	 lung	 cancer,	
independent	of	smoking.	Clin	Infect	Dis,	2007.	45(1):	p.	103-10.	17.	 Olalekan,	S.A.,	et	al.,	B	cells	expressing	IFN-gamma	suppress	Treg-cell	differentiation	and	
promote	autoimmune	experimental	arthritis.	Eur	J	Immunol,	2015.	45(4):	p.	988-98.	18.	 Hu,	C.Y.,	et	al.,	Treatment	with	CD20-specific	antibody	prevents	and	reverses	autoimmune	
diabetes	in	mice.	J	Clin	Invest,	2007.	117(12):	p.	3857-67.	19.	 Bouaziz,	J.D.,	et	al.,	Therapeutic	B	cell	depletion	impairs	adaptive	and	autoreactive	CD4+	
T	cell	activation	in	mice.	Proc	Natl	Acad	Sci	U	S	A,	2007.	104(52):	p.	20878-83.	20.	 Lund,	 F.E.,	 Cytokine-producing	 B	 lymphocytes-key	 regulators	 of	 immunity.	 Curr	 Opin	Immunol,	2008.	20(3):	p.	332-8.	21.	 Crawford,	A.,	et	al.,	Primary	T	cell	expansion	and	differentiation	in	vivo	requires	antigen	
presentation	by	B	cells.	J	Immunol,	2006.	176(6):	p.	3498-506.	22.	 Maletzki,	 C.,	 et	 al.,	 Ex-vivo	 clonally	 expanded	 B	 lymphocytes	 infiltrating	 colorectal	
carcinoma	are	of	mature	immunophenotype	and	produce	functional	IgG.	PLoS	One,	2012.	
7(2):	p.	e32639.	23.	 Nielsen,	J.S.,	et	al.,	CD20+	tumor-infiltrating	lymphocytes	have	an	atypical	CD27-	memory	
phenotype	and	together	with	CD8+	T	cells	promote	favorable	prognosis	in	ovarian	cancer.	Clin	Cancer	Res,	2012.	18(12):	p.	3281-92.	
	 96	
24.	 Shi,	J.Y.,	et	al.,	Margin-infiltrating	CD20(+)	B	cells	display	an	atypical	memory	phenotype	
and	 correlate	 with	 favorable	 prognosis	 in	 hepatocellular	 carcinoma.	 Clin	 Cancer	 Res,	2013.	19(21):	p.	5994-6005.	25.	 Ahmadi,	 T.,	 et	 al.,	 CD40	 Ligand-activated,	 antigen-specific	 B	 cells	 are	 comparable	 to	
mature	 dendritic	 cells	 in	 presenting	 protein	 antigens	 and	 major	 histocompatibility	
complex	class	I-	and	class	II-binding	peptides.	Immunology,	2008.	124(1):	p.	129-40.	26.	 Gnjatic,	 S.,	 et	 al.,	Cross-presentation	 of	HLA	 class	 I	 epitopes	 from	 exogenous	NY-ESO-1	
polypeptides	by	nonprofessional	APCs.	J	Immunol,	2003.	170(3):	p.	1191-6.	27.	 Rodriguez-Pinto,	D.,	B	cells	as	antigen	presenting	cells.	Cell	Immunol,	2005.	238(2):	p.	67-75.	28.	 Nelson,	B.H.,	CD20+	B	cells:	 the	other	tumor-infiltrating	lymphocytes.	 J	Immunol,	2010.	
185(9):	p.	4977-82.	29.	 Al-Shibli,	K.I.,	et	al.,	Prognostic	effect	of	epithelial	and	stromal	lymphocyte	infiltration	in	
non-small	cell	lung	cancer.	Clin	Cancer	Res,	2008.	14(16):	p.	5220-7.	30.	 Nedergaard,	B.S.,	et	al.,	A	comparative	study	of	the	cellular	immune	response	in	patients	
with	 stage	 IB	 cervical	 squamous	 cell	 carcinoma.	 Low	 numbers	 of	 several	 immune	 cell	
subtypes	are	strongly	associated	with	relapse	of	disease	within	5	years.	Gynecol	Oncol,	2008.	108(1):	p.	106-11.	31.	 Lundgren,	S.,	 et	al.,	Prognostic	 impact	of	 tumour-associated	B	cells	and	plasma	cells	 in	
epithelial	ovarian	cancer.	J	Ovarian	Res,	2016.	9:	p.	21.	32.	 Kornbluth,	R.S.,	M.	Stempniak,	and	G.W.	Stone,	Design	of	CD40	agonists	and	their	use	in	
growing	B	cells	for	cancer	immunotherapy.	Int	Rev	Immunol,	2012.	31(4):	p.	279-88.	33.	 Silina,	 K.,	 et	 al.,	 Manipulation	 of	 tumour-infiltrating	 B	 cells	 and	 tertiary	 lymphoid	
structures:	a	novel	anti-cancer	treatment	avenue?	Cancer	Immunol	Immunother,	2014.	
63(7):	p.	643-62.	34.	 Aloisi,	F.	and	R.	Pujol-Borrell,	Lymphoid	neogenesis	in	chronic	inflammatory	diseases.	Nat	Rev	Immunol,	2006.	6(3):	p.	205-17.	35.	 Carragher,	D.M.,	et	al.,	A	novel	role	for	non-neutralizing	antibodies	against	nucleoprotein	
in	facilitating	resistance	to	influenza	virus.	J	Immunol,	2008.	181(6):	p.	4168-76.	36.	 Neyt,	K.,	et	al.,	Tertiary	lymphoid	organs	in	infection	and	autoimmunity.	Trends	Immunol,	2012.	33(6):	p.	297-305.	37.	 Dieu-Nosjean,	M.C.,	 et	 al.,	Tertiary	 lymphoid	 structures	 in	 cancer	 and	 beyond.	 Trends	Immunol,	2014.	35(11):	p.	571-80.	38.	 Pitzalis,	C.,	et	al.,	Ectopic	lymphoid-like	structures	in	infection,	cancer	and	autoimmunity.	Nat	Rev	Immunol,	2014.	14(7):	p.	447-62.	39.	 Moyron-Quiroz,	J.E.,	et	al.,	Role	of	inducible	bronchus	associated	lymphoid	tissue	(iBALT)	
in	respiratory	immunity.	Nat	Med,	2004.	10(9):	p.	927-34.	40.	 de	 Chaisemartin,	 L.,	 et	 al.,	 Characterization	 of	 chemokines	 and	 adhesion	 molecules	
associated	with	 T	 cell	 presence	 in	 tertiary	 lymphoid	 structures	 in	 human	 lung	 cancer.	Cancer	Res,	2011.	71(20):	p.	6391-9.	41.	 Di	Caro,	G.	and	F.	Marchesi,	Tertiary	lymphoid	tissue:	A	gateway	for	T	cells	in	the	tumor	
microenvironment.	Oncoimmunology,	2014.	3:	p.	e28850.	42.	 Lutz,	 E.R.,	 et	 al.,	 Immunotherapy	 converts	 nonimmunogenic	 pancreatic	 tumors	 into	
immunogenic	foci	of	immune	regulation.	Cancer	Immunol	Res,	2014.	2(7):	p.	616-31.	43.	 Murakami,	J.,	et	al.,	Functional	B-cell	response	in	intrahepatic	lymphoid	follicles	in	chronic	
hepatitis	C.	Hepatology,	1999.	30(1):	p.	143-50.	44.	 Armengol,	M.P.,	 et	 al.,	Thyroid	autoimmune	disease:	demonstration	of	 thyroid	antigen-
specific	 B	 cells	 and	 recombination-activating	 gene	 expression	 in	 chemokine-containing	
active	intrathyroidal	germinal	centers.	Am	J	Pathol,	2001.	159(3):	p.	861-73.	
	 97	
45.	 Manzo,	A.,	et	al.,	Secondary	and	ectopic	lymphoid	tissue	responses	in	rheumatoid	arthritis:	
from	inflammation	to	autoimmunity	and	tissue	damage/remodeling.	Immunol	Rev,	2010.	
233(1):	p.	267-85.	46.	 Di	 Caro,	 G.,	 et	 al.,	 Tertiary	 lymphoid	 tissue	 in	 the	 tumor	 microenvironment:	 from	 its	
occurrence	to	immunotherapeutic	implications.	Int	Rev	Immunol,	2015.	34(2):	p.	123-33.	47.	 Dieu-Nosjean,	M.C.,	et	al.,	Long-term	survival	for	patients	with	non-small-cell	lung	cancer	
with	intratumoral	lymphoid	structures.	J	Clin	Oncol,	2008.	26(27):	p.	4410-7.	48.	 Cipponi,	 A.,	 et	 al.,	Neogenesis	 of	 lymphoid	 structures	 and	 antibody	 responses	 occur	 in	
human	melanoma	metastases.	Cancer	Res,	2012.	72(16):	p.	3997-4007.	49.	 Coppola,	D.,	et	al.,	Unique	ectopic	lymph	node-like	structures	present	in	human	primary	
colorectal	carcinoma	are	identified	by	immune	gene	array	profiling.	Am	J	Pathol,	2011.	
179(1):	p.	37-45.	50.	 Bergomas,	F.,	 et	 al.,	Tertiary	 intratumor	 lymphoid	 tissue	 in	 colo-rectal	 cancer.	 Cancers	(Basel),	2011.	4(1):	p.	1-10.	51.	 Martinet,	L.,	et	al.,	Human	solid	tumors	contain	high	endothelial	venules:	association	with	
T-	and	B-lymphocyte	 infiltration	and	 favorable	 prognosis	 in	breast	 cancer.	 Cancer	Res,	2011.	71(17):	p.	5678-87.	52.	 Goc,	 J.,	 et	 al.,	 Characteristics	 of	 tertiary	 lymphoid	 structures	 in	 primary	 cancers.	Oncoimmunology,	2013.	2(12):	p.	e26836.	53.	 Finkin,	S.,	et	al.,	Ectopic	lymphoid	structures	function	as	microniches	for	tumor	progenitor	
cells	in	hepatocellular	carcinoma.	Nat	Immunol,	2015.	16(12):	p.	1235-44.	54.	 Galluzzi,	L.,	G.	Kroemer,	and	A.	Eggermont,	Novel	immune	checkpoint	blocker	approved	
for	the	treatment	of	advanced	melanoma.	Oncoimmunology,	2014.	3(11):	p.	e967147.	55.	 Lesterhuis,	W.J.,	 J.B.	Haanen,	 and	 C.J.	 Punt,	Cancer	 immunotherapy--revisited.	 Nat	 Rev	Drug	Discov,	2011.	10(8):	p.	591-600.	56.	 Smyth,	 M.J.,	 et	 al.,	 Combination	 cancer	 immunotherapies	 tailored	 to	 the	 tumour	
microenvironment.	Nat	Rev	Clin	Oncol,	2016.	13(3):	p.	143-58.	57.	 Kroemer,	G.,	et	al.,	Natural	and	therapy-induced	immunosurveillance	in	breast	cancer.	Nat	Med,	2015.	21(10):	p.	1128-38.	58.	 Marabondo,	 S.	 and	 H.L.	 Kaufman,	High-dose	 interleukin-2	 (IL-2)	 for	 the	 treatment	 of	
melanoma:	 safety	 considerations	 and	 future	 directions.	 Expert	 Opin	 Drug	 Saf,	 2017.	
16(12):	p.	1347-1357.	59.	 Kirkwood,	 J.M.,	G.D.	Resnick,	and	B.F.	Cole,	Efficacy,	 safety,	and	risk-benefit	analysis	of	
adjuvant	interferon	alfa-2b	in	melanoma.	Semin	Oncol,	1997.	24(1	Suppl	4):	p.	S16-23.	60.	 Anderson,	 P.,	 M.	 Hoglund,	 and	 S.	 Rodjer,	 Pulmonary	 side	 effects	 of	 interferon-alpha	
therapy	in	patients	with	hematological	malignancies.	Am	J	Hematol,	2003.	73(1):	p.	54-8.	61.	 Pol,	 J.,	 et	 al.,	Trial	Watch:	 Peptide-based	 anticancer	 vaccines.	 Oncoimmunology,	 2015.	
4(4):	p.	e974411.	62.	 Garg,	 A.D.,	 et	 al.,	 Trial	 watch:	 Dendritic	 cell-based	 anticancer	 immunotherapy.	Oncoimmunology,	2017.	6(7):	p.	e1328341.	63.	 Fournier,	 C.,	 et	 al.,	 Trial	 Watch:	 Adoptively	 transferred	 cells	 for	 anticancer	
immunotherapy.	Oncoimmunology,	2017.	6(11):	p.	e1363139.	64.	 Topalian,	S.L.,	et	al.,	Mechanism-driven	biomarkers	to	guide	immune	checkpoint	blockade	
in	cancer	therapy.	Nat	Rev	Cancer,	2016.	16(5):	p.	275-87.	65.	 Topalian,	S.L.,	et	al.,	Survival,	durable	tumor	remission,	and	long-term	safety	in	patients	
with	advanced	melanoma	receiving	nivolumab.	J	Clin	Oncol,	2014.	32(10):	p.	1020-30.	66.	 Motzer,	 R.J.,	 et	 al.,	 Nivolumab	 for	 Metastatic	 Renal	 Cell	 Carcinoma:	 Results	 of	 a	
Randomized	Phase	II	Trial.	J	Clin	Oncol,	2015.	33(13):	p.	1430-7.	67.	 Borghaei,	H.,	et	al.,	Nivolumab	versus	Docetaxel	in	Advanced	Nonsquamous	Non-Small-Cell	
Lung	Cancer.	N	Engl	J	Med,	2015.	373(17):	p.	1627-39.	
	 98	
68.	 Galon,	 J.,	 et	 al.,	Towards	 the	 introduction	 of	 the	 'Immunoscore'	 in	 the	 classification	 of	
malignant	tumours.	J	Pathol,	2014.	232(2):	p.	199-209.	69.	 Fridman,	 W.H.,	 et	 al.,	 The	 immune	 contexture	 in	 human	 tumours:	 impact	 on	 clinical	
outcome.	Nat	Rev	Cancer,	2012.	12(4):	p.	298-306.	70.	 Galon,	 J.,	 et	 al.,	Cancer	 classification	 using	 the	 Immunoscore:	 a	worldwide	 task	 force.	 J	Transl	Med,	2012.	10:	p.	205.	71.	 Restifo,	N.P.,	A	"big	data"	view	of	the	tumor	"immunome".	Immunity,	2013.	39(4):	p.	631-2.	72.	 Bindea,	 G.,	 et	 al.,	 Spatiotemporal	 dynamics	 of	 intratumoral	 immune	 cells	 reveal	 the	
immune	landscape	in	human	cancer.	Immunity,	2013.	39(4):	p.	782-95.	73.	 Fridman,	W.H.,	et	al.,	The	immune	contexture	in	cancer	prognosis	and	treatment.	Nat	Rev	Clin	Oncol,	2017.	14(12):	p.	717-734.	74.	 Bardeesy,	N.	and	R.A.	DePinho,	Pancreatic	cancer	biology	and	genetics.	Nat	Rev	Cancer,	2002.	2(12):	p.	897-909.	75.	 Siegel,	R.L.,	K.D.	Miller,	and	A.	Jemal,	Cancer	statistics,	2018.	CA	Cancer	J	Clin,	2018.	68(1):	p.	7-30.	76.	 Clark,	C.E.,	et	al.,	Dynamics	of	the	immune	reaction	to	pancreatic	cancer	from	inception	to	
invasion.	Cancer	Res,	2007.	67(19):	p.	9518-27.	77.	 Ino,	Y.,	et	al.,	Immune	cell	infiltration	as	an	indicator	of	the	immune	microenvironment	of	
pancreatic	cancer.	Br	J	Cancer,	2013.	108(4):	p.	914-23.	78.	 Kurahara,	 H.,	 et	 al.,	 Significance	 of	 M2-polarized	 tumor-associated	 macrophage	 in	
pancreatic	cancer.	J	Surg	Res,	2011.	167(2):	p.	e211-9.	79.	 Bayne,	 L.J.,	 et	 al.,	 Tumor-derived	 granulocyte-macrophage	 colony-stimulating	 factor	
regulates	myeloid	 inflammation	and	T	 cell	 immunity	 in	pancreatic	cancer.	 Cancer	Cell,	2012.	21(6):	p.	822-35.	80.	 Pylayeva-Gupta,	 Y.,	 et	 al.,	 Oncogenic	 Kras-induced	 GM-CSF	 production	 promotes	 the	
development	of	pancreatic	neoplasia.	Cancer	Cell,	2012.	21(6):	p.	836-47.	81.	 Hiraoka,	 N.,	 et	 al.,	 Prevalence	 of	 FOXP3+	 regulatory	 T	 cells	 increases	 during	 the	
progression	 of	 pancreatic	 ductal	 adenocarcinoma	 and	 its	 premalignant	 lesions.	 Clin	Cancer	Res,	2006.	12(18):	p.	5423-34.	82.	 Zheng,	L.,	 et	 al.,	Role	 of	 immune	 cells	and	 immune-based	 therapies	 in	pancreatitis	and	
pancreatic	ductal	adenocarcinoma.	Gastroenterology,	2013.	144(6):	p.	1230-40.	83.	 Soares,	K.C.,	et	al.,	PD-1/PD-L1	blockade	together	with	vaccine	therapy	facilitates	effector	
T-cell	infiltration	into	pancreatic	tumors.	J	Immunother,	2015.	38(1):	p.	1-11.	84.	 Winograd,	R.,	et	al.,	Induction	of	T-cell	Immunity	Overcomes	Complete	Resistance	to	PD-1	
and	CTLA-4	Blockade	and	Improves	Survival	in	Pancreatic	Carcinoma.	Cancer	Immunol	Res,	2015.	3(4):	p.	399-411.	85.	 Carstens,	J.L.,	et	al.,	Spatial	computation	of	intratumoral	T	cells	correlates	with	survival	of	
patients	with	pancreatic	cancer.	Nat	Commun,	2017.	8:	p.	15095.	86.	 Erkan,	 M.,	 et	 al.,	 The	 role	 of	 stroma	 in	 pancreatic	 cancer:	 diagnostic	 and	 therapeutic	
implications.	Nat	Rev	Gastroenterol	Hepatol,	2012.	9(8):	p.	454-67.	87.	 Kraman,	 M.,	 et	 al.,	 Suppression	 of	 antitumor	 immunity	 by	 stromal	 cells	 expressing	
fibroblast	activation	protein-alpha.	Science,	2010.	330(6005):	p.	827-30.	88.	 Ene-Obong,	A.,	et	al.,	Activated	pancreatic	stellate	cells	sequester	CD8+	T	cells	to	reduce	
their	infiltration	of	the	juxtatumoral	compartment	of	pancreatic	ductal	adenocarcinoma.	Gastroenterology,	2013.	145(5):	p.	1121-32.	89.	 Tjomsland,	V.,	et	al.,	The	desmoplastic	stroma	plays	an	essential	role	in	the	accumulation	
and	 modulation	 of	 infiltrated	 immune	 cells	 in	 pancreatic	 adenocarcinoma.	 Clin	 Dev	Immunol,	2011.	2011:	p.	212810.	
	 99	
90.	 Erkan,	M.,	et	al.,	The	activated	stroma	index	is	a	novel	and	independent	prognostic	marker	
in	pancreatic	ductal	adenocarcinoma.	Clin	Gastroenterol	Hepatol,	2008.	6(10):	p.	1155-61.	91.	 Kroemer,	G.	and	J.	Pouyssegur,	Tumor	cell	metabolism:	cancer's	Achilles'	heel.	Cancer	Cell,	2008.	13(6):	p.	472-82.	92.	 Martinez-Outschoorn,	U.E.,	et	al.,	Cancer	metabolism:	a	therapeutic	perspective.	Nat	Rev	Clin	Oncol,	2017.	14(1):	p.	11-31.	93.	 Kelderman,	 S.,	 et	 al.,	 Lactate	 dehydrogenase	 as	 a	 selection	 criterion	 for	 ipilimumab	
treatment	in	metastatic	melanoma.	Cancer	Immunol	Immunother,	2014.	63(5):	p.	449-58.	94.	 Pearce,	E.L.	and	E.J.	Pearce,	Metabolic	pathways	in	immune	cell	activation	and	quiescence.	Immunity,	2013.	38(4):	p.	633-43.	95.	 Ward,	 P.S.	 and	 C.B.	 Thompson,	 Metabolic	 reprogramming:	 a	 cancer	 hallmark	 even	
warburg	did	not	anticipate.	Cancer	Cell,	2012.	21(3):	p.	297-308.	96.	 Warburg,	O.,	On	respiratory	impairment	in	cancer	cells.	Science,	1956.	124(3215):	p.	269-70.	97.	 Pfeiffer,	T.,	S.	Schuster,	and	S.	Bonhoeffer,	Cooperation	and	competition	in	the	evolution	
of	ATP-producing	pathways.	Science,	2001.	292(5516):	p.	504-7.	98.	 Vander	Heiden,	M.G.,	L.C.	Cantley,	and	C.B.	Thompson,	Understanding	the	Warburg	effect:	
the	metabolic	requirements	of	cell	proliferation.	Science,	2009.	324(5930):	p.	1029-33.	99.	 Wang,	R.	and	D.R.	Green,	Metabolic	checkpoints	in	activated	T	cells.	Nat	Immunol,	2012.	
13(10):	p.	907-15.	100.	 Rafalski,	V.A.,	E.	Mancini,	and	A.	Brunet,	Energy	metabolism	and	energy-sensing	pathways	
in	mammalian	embryonic	and	adult	stem	cell	fate.	J	Cell	Sci,	2012.	125(Pt	23):	p.	5597-608.	101.	 Harvey,	 A.J.,	 K.L.	 Kind,	 and	 J.G.	 Thompson,	 REDOX	 regulation	 of	 early	 embryo	
development.	Reproduction,	2002.	123(4):	p.	479-86.	102.	 O'Neill,	 L.A.,	 R.J.	 Kishton,	 and	 J.	 Rathmell,	 A	 guide	 to	 immunometabolism	 for	
immunologists.	Nat	Rev	Immunol,	2016.	16(9):	p.	553-65.	103.	 Chang,	C.H.,	et	al.,	Metabolic	Competition	in	the	Tumor	Microenvironment	Is	a	Driver	of	
Cancer	Progression.	Cell,	2015.	162(6):	p.	1229-41.	104.	 Russo,	V.	and	M.P.	Protti,	Tumor-derived	factors	affecting	immune	cells.	Cytokine	Growth	Factor	Rev,	2017.	36:	p.	79-87.	105.	 Molon,	B.,	B.	Cali,	and	A.	Viola,	T	Cells	and	Cancer:	How	Metabolism	Shapes	 Immunity.	Front	Immunol,	2016.	7:	p.	20.	106.	 Corrado,	M.,	L.	Scorrano,	and	S.	Campello,	Changing	perspective	on	oncometabolites:	from	
metabolic	signature	of	cancer	to	tumorigenic	and	immunosuppressive	agents.	Oncotarget,	2016.	7(29):	p.	46692-46706.	107.	 Renner,	 K.,	 et	 al.,	 Metabolic	 Hallmarks	 of	 Tumor	 and	 Immune	 Cells	 in	 the	 Tumor	
Microenvironment.	Front	Immunol,	2017.	8:	p.	248.	108.	 Calcinotto,	A.,	et	al.,	Modulation	of	microenvironment	acidity	reverses	anergy	in	human	
and	murine	tumor-infiltrating	T	lymphocytes.	Cancer	Res,	2012.	72(11):	p.	2746-56.	109.	 Vander	 Heiden,	 M.G.	 and	 R.J.	 DeBerardinis,	 Understanding	 the	 Intersections	 between	
Metabolism	and	Cancer	Biology.	Cell,	2017.	168(4):	p.	657-669.	110.	 Vander	Heiden,	M.G.,	Targeting	cancer	metabolism:	a	therapeutic	window	opens.	Nat	Rev	Drug	Discov,	2011.	10(9):	p.	671-84.	111.	 Galluzzi,	 L.,	 et	 al.,	Metabolic	 targets	 for	 cancer	 therapy.	 Nat	 Rev	 Drug	 Discov,	 2013.	
12(11):	p.	829-46.	112.	 Marchiq,	I.	and	J.	Pouyssegur,	Hypoxia,	cancer	metabolism	and	the	therapeutic	benefit	of	
targeting	lactate/H(+)	symporters.	J	Mol	Med	(Berl),	2016.	94(2):	p.	155-71.	
	 100	
113.	 Melero,	 I.,	 et	 al.,	 Evolving	 synergistic	 combinations	 of	 targeted	 immunotherapies	 to	
combat	cancer.	Nat	Rev	Cancer,	2015.	15(8):	p.	457-72.	114.	 Sukumar,	 M.,	 R.J.	 Kishton,	 and	 N.P.	 Restifo,	 Metabolic	 reprograming	 of	 anti-tumor	
immunity.	Curr	Opin	Immunol,	2017.	46:	p.	14-22.	115.	 Pearce,	E.L.,	et	al.,	Enhancing	CD8	T-cell	memory	by	modulating	 fatty	acid	metabolism.	Nature,	2009.	460(7251):	p.	103-7.	116.	 Michalek,	 R.D.,	 et	 al.,	 Cutting	 edge:	 distinct	 glycolytic	 and	 lipid	 oxidative	 metabolic	
programs	are	essential	for	effector	and	regulatory	CD4+	T	cell	subsets.	J	Immunol,	2011.	
186(6):	p.	3299-303.	117.	 Klebanoff,	C.A.,	 et	al.,	Central	memory	self/tumor-reactive	CD8+	T	cells	confer	 superior	
antitumor	 immunity	compared	with	effector	memory	T	cells.	 Proc	Natl	Acad	Sci	U	S	A,	2005.	102(27):	p.	9571-6.	118.	 Gattinoni,	L.,	et	al.,	Wnt	signaling	arrests	effector	T	cell	differentiation	and	generates	CD8+	
memory	stem	cells.	Nat	Med,	2009.	15(7):	p.	808-13.	119.	 Zanon,	V.,	 et	 al.,	Curtailed	T-cell	 activation	 curbs	 effector	differentiation	and	generates	
CD8(+)	T	cells	with	a	naturally-occurring	memory	stem	cell	phenotype.	Eur	 J	 Immunol,	2017.	47(9):	p.	1468-1476.	120.	 Lugli,	E.,	et	al.,	Identification,	isolation	and	in	vitro	expansion	of	human	and	nonhuman	
primate	T	stem	cell	memory	cells.	Nat	Protoc,	2013.	8(1):	p.	33-42.	121.	 Gattinoni,	L.,	et	al.,	A	human	memory	T	cell	subset	with	stem	cell-like	properties.	Nat	Med,	2011.	17(10):	p.	1290-7.	122.	 Cieri,	N.,	et	al.,	IL-7	and	IL-15	instruct	the	generation	of	human	memory	stem	T	cells	from	
naive	precursors.	Blood,	2013.	121(4):	p.	573-84.	123.	 Sukumar,	M.,	et	al.,	 Inhibiting	glycolytic	metabolism	enhances	CD8+	T	cell	memory	and	
antitumor	function.	J	Clin	Invest,	2013.	123(10):	p.	4479-88.	124.	 Cappello,	P.,	et	al.,	Vaccination	with	ENO1	DNA	prolongs	survival	of	genetically	engineered	
mice	with	pancreatic	cancer.	Gastroenterology,	2013.	144(5):	p.	1098-106.	125.	 Altman,	 D.G.,	 et	 al.,	 Reporting	 recommendations	 for	 tumor	 marker	 prognostic	 studies	
(REMARK):	explanation	and	elaboration.	BMC	Med,	2012.	10:	p.	51.	126.	 Siegel,	R.L.,	K.D.	Miller,	and	A.	Jemal,	Cancer	Statistics,	2017.	CA	Cancer	J	Clin,	2017.	67(1):	p.	7-30.	127.	 Di	 Caro,	 G.,	 et	 al.,	 Occurrence	 of	 tertiary	 lymphoid	 tissue	 is	 associated	 with	 T-cell	
infiltration	and	 predicts	better	prognosis	 in	 early-stage	 colorectal	 cancers.	 Clin	Cancer	Res,	2014.	20(8):	p.	2147-58.	128.	 de	 Visser,	 K.E.,	 L.V.	 Korets,	 and	 L.M.	 Coussens,	 De	 novo	 carcinogenesis	 promoted	 by	
chronic	inflammation	is	B	lymphocyte	dependent.	Cancer	Cell,	2005.	7(5):	p.	411-23.	129.	 Kroeger,	D.R.,	K.	Milne,	and	B.H.	Nelson,	Tumor-Infiltrating	Plasma	Cells	Are	Associated	
with	Tertiary	Lymphoid	Structures,	Cytolytic	T-Cell	Responses,	and	Superior	Prognosis	in	
Ovarian	Cancer.	Clin	Cancer	Res,	2016.	22(12):	p.	3005-15.	130.	 Thaunat,	O.,	et	al.,	B	cell	survival	in	intragraft	tertiary	lymphoid	organs	after	rituximab	
therapy.	Transplantation,	2008.	85(11):	p.	1648-53.	131.	 Martin,	 F.	 and	A.C.	 Chan,	B	 cell	 immunobiology	 in	 disease:	 evolving	 concepts	 from	 the	
clinic.	Annu	Rev	Immunol,	2006.	24:	p.	467-96.	132.	 Gunderson,	A.J.	and	L.M.	Coussens,	B	cells	and	their	mediators	as	targets	for	therapy	in	
solid	tumors.	Exp	Cell	Res,	2013.	319(11):	p.	1644-9.	133.	 Barbera-Guillem,	 E.,	 et	 al.,	 B	 lymphocyte	 pathology	 in	 human	 colorectal	 cancer.	
Experimental	and	clinical	therapeutic	effects	of	partial	B	cell	depletion.	Cancer	Immunol	Immunother,	2000.	48(10):	p.	541-9.	134.	 Aklilu,	M.,	et	al.,	Depletion	of	normal	B	cells	with	rituximab	as	an	adjunct	to	IL-2	therapy	
for	renal	cell	carcinoma	and	melanoma.	Ann	Oncol,	2004.	15(7):	p.	1109-14.	
	 101	
135.	 Affara,	N.I.,	et	al.,	B	cells	regulate	macrophage	phenotype	and	response	to	chemotherapy	
in	squamous	carcinomas.	Cancer	Cell,	2014.	25(6):	p.	809-821.	136.	 Zhang,	Y.,	et	al.,	B	cell	regulation	of	anti-tumor	 immune	response.	 Immunol	Res,	2013.	
57(1-3):	p.	115-24.	137.	 Zhang,	Y.,	et	al.,	B	lymphocyte	inhibition	of	anti-tumor	response	depends	on	expansion	of	
Treg	but	 is	 independent	of	B-cell	 IL-10	 secretion.	 Cancer	 Immunol	 Immunother,	2013.	
62(1):	p.	87-99.	138.	 Shah,	S.,	et	al.,	Increased	rejection	of	primary	tumors	in	mice	lacking	B	cells:	inhibition	of	
anti-tumor	CTL	and	TH1	cytokine	responses	by	B	cells.	Int	J	Cancer,	2005.	117(4):	p.	574-86.	139.	 Qin,	Z.,	et	al.,	B	cells	inhibit	induction	of	T	cell-dependent	tumor	immunity.	Nat	Med,	1998.	
4(5):	p.	627-30.	140.	 Perricone,	 M.A.,	 et	 al.,	 Enhanced	 efficacy	 of	 melanoma	 vaccines	 in	 the	 absence	 of	 B	
lymphocytes.	J	Immunother,	2004.	27(4):	p.	273-81.	141.	 Inoue,	 S.,	 et	 al.,	 Inhibitory	 effects	 of	 B	 cells	 on	antitumor	 immunity.	 Cancer	Res,	 2006.	
66(15):	p.	7741-7.	142.	 Kim,	S.,	et	al.,	B-cell	depletion	using	an	anti-CD20	antibody	augments	antitumor	immune	
responses	and	immunotherapy	in	nonhematopoetic	murine	tumor	models.	J	Immunother,	2008.	31(5):	p.	446-57.	143.	 Forte,	G.,	 et	 al.,	 Inhibition	of	CD73	 improves	B	 cell-mediated	anti-tumor	 immunity	 in	a	
mouse	model	of	melanoma.	J	Immunol,	2012.	189(5):	p.	2226-33.	144.	 DiLillo,	D.J.,	K.	Yanaba,	and	T.F.	Tedder,	B	cells	are	required	for	optimal	CD4+	and	CD8+	T	
cell	tumor	immunity:	therapeutic	B	cell	depletion	enhances	B16	melanoma	growth	in	mice.	J	Immunol,	2010.	184(7):	p.	4006-16.	145.	 Pollizzi,	K.N.	and	J.D.	Powell,	Integrating	canonical	and	metabolic	signalling	programmes	
in	the	regulation	of	T	cell	responses.	Nat	Rev	Immunol,	2014.	14(7):	p.	435-46.	146.	 MacIver,	N.J.,	 R.D.	Michalek,	 and	 J.C.	 Rathmell,	Metabolic	 regulation	 of	 T	 lymphocytes.	Annu	Rev	Immunol,	2013.	31:	p.	259-83.	147.	 Fox,	C.J.,	P.S.	Hammerman,	and	C.B.	Thompson,	Fuel	feeds	function:	energy	metabolism	
and	the	T-cell	response.	Nat	Rev	Immunol,	2005.	5(11):	p.	844-52.	148.	 Norata,	G.D.,	et	al.,	The	Cellular	and	Molecular	Basis	of	Translational	Immunometabolism.	Immunity,	2015.	43(3):	p.	421-34.	149.	 Feig,	C.,	et	al.,	Targeting	CXCL12	 from	FAP-expressing	carcinoma-associated	 fibroblasts	
synergizes	with	anti-PD-L1	immunotherapy	in	pancreatic	cancer.	Proc	Natl	Acad	Sci	U	S	A,	2013.	110(50):	p.	20212-7.	150.	 Beatty,	G.L.,	et	al.,	Exclusion	of	T	Cells	From	Pancreatic	Carcinomas	in	Mice	Is	Regulated	
by	Ly6C(low)	F4/80(+)	Extratumoral	Macrophages.	Gastroenterology,	2015.	149(1):	p.	201-10.	151.	 Yu,	 J.,	 et	 al.,	Digital	 next-generation	 sequencing	 identifies	 low-abundance	mutations	 in	
pancreatic	juice	samples	collected	from	the	duodenum	of	patients	with	pancreatic	cancer	
and	intraductal	papillary	mucinous	neoplasms.	Gut,	2017.	66(9):	p.	1677-1687.	152.	 Hart,	 C.D.,	 et	 al.,	 Serum	Metabolomic	 Profiles	 Identify	 ER-Positive	 Early	 Breast	 Cancer	
Patients	at	Increased	Risk	of	Disease	Recurrence	in	a	Multicenter	Population.	Clin	Cancer	Res,	2017.	23(6):	p.	1422-1431.	153.	 Takis,	P.G.,	et	al.,	(1)H-NMR	based	metabolomics	study	for	the	detection	of	the	human	urine	
metabolic	profile	effects	of	Origanum	dictamnus	tea	ingestion.	Food	Funct,	2016.	7(9):	p.	4104-15.	154.	 Bathe,	 O.F.,	 et	 al.,	 Feasibility	 of	 identifying	 pancreatic	 cancer	 based	 on	 serum	
metabolomics.	Cancer	Epidemiol	Biomarkers	Prev,	2011.	20(1):	p.	140-7.	
	 102	
155.	 Napoli,	C.,	et	al.,	Urine	metabolic	signature	of	pancreatic	ductal	adenocarcinoma	by	(1)h	
nuclear	 magnetic	 resonance:	 identification,	 mapping,	 and	 evolution.	 J	 Proteome	 Res,	2012.	11(2):	p.	1274-83.	156.	 Sugimoto,	 M.,	 et	 al.,	 Capillary	 electrophoresis	 mass	 spectrometry-based	 saliva	
metabolomics	 identified	 oral,	 breast	 and	 pancreatic	 cancer-specific	 profiles.	Metabolomics,	2010.	6(1):	p.	78-95.	157.	 Zamarin,	D.,	et	al.,	Localized	oncolytic	virotherapy	overcomes	systemic	tumor	resistance	to	
immune	checkpoint	blockade	immunotherapy.	Sci	Transl	Med,	2014.	6(226):	p.	226ra32.	158.	 Taube,	 J.M.,	 et	 al.,	 Colocalization	 of	 inflammatory	 response	 with	 B7-h1	 expression	 in	
human	melanocytic	lesions	supports	an	adaptive	resistance	mechanism	of	immune	escape.	Sci	Transl	Med,	2012.	4(127):	p.	127ra37.	159.	 Weide,	B.,	 et	 al.,	Baseline	Biomarkers	 for	Outcome	of	Melanoma	Patients	Treated	with	
Pembrolizumab.	Clin	Cancer	Res,	2016.	22(22):	p.	5487-5496.	160.	 Martens,	A.,	et	al.,	Baseline	Peripheral	Blood	Biomarkers	Associated	with	Clinical	Outcome	
of	Advanced	Melanoma	Patients	Treated	with	Ipilimumab.	Clin	Cancer	Res,	2016.	22(12):	p.	2908-18.	161.	 Haas,	R.,	et	al.,	Lactate	Regulates	Metabolic	and	Pro-inflammatory	Circuits	in	Control	of	T	
Cell	Migration	and	Effector	Functions.	PLoS	Biol,	2015.	13(7):	p.	e1002202.	162.	 Fischer,	K.,	et	al.,	Inhibitory	effect	of	tumor	cell-derived	lactic	acid	on	human	T	cells.	Blood,	2007.	109(9):	p.	3812-9.	163.	 Brand,	 A.,	 et	 al.,	 LDHA-Associated	 Lactic	 Acid	 Production	 Blunts	 Tumor	
Immunosurveillance	by	T	and	NK	Cells.	Cell	Metab,	2016.	24(5):	p.	657-671.	164.	 Wherry,	E.J.,	 et	 al.,	Molecular	 signature	of	CD8+	T	 cell	 exhaustion	during	 chronic	 viral	
infection.	Immunity,	2007.	27(4):	p.	670-84.	165.	 Schietinger,	A.	and	P.D.	Greenberg,	Tolerance	and	exhaustion:	defining	mechanisms	of	T	
cell	dysfunction.	Trends	Immunol,	2014.	35(2):	p.	51-60.	166.	 Patsoukis,	N.,	et	al.,	PD-1	alters	T-cell	metabolic	reprogramming	by	inhibiting	glycolysis	
and	promoting	lipolysis	and	fatty	acid	oxidation.	Nat	Commun,	2015.	6:	p.	6692.	167.	 Badoual,	C.,	et	al.,	PD-1-expressing	tumor-infiltrating	T	cells	are	a	 favorable	prognostic	
biomarker	in	HPV-associated	head	and	neck	cancer.	Cancer	Res,	2013.	73(1):	p.	128-38.	168.	 Sauce,	 D.,	 et	 al.,	 PD-1	 expression	 on	 human	 CD8	 T	 cells	 depends	 on	 both	 state	 of	
differentiation	and	activation	status.	AIDS,	2007.	21(15):	p.	2005-13.		
 
